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 1. INTRODUCTION 
 
The traditional use of excipients in drug formulations was to act as inert 
vehicles to provided necessary weight, consistency and volume for the correct 
administration of the active ingredient, but in modern pharmaceutical dosage forms 
they often full fill multi- functional rules such as modifying release, improvement of 
this ability and bioavailability of the active ingredient, enhancement of patient 
acceptability and ensure ease of manufacture. New and improved excipients continue 
 
to be developed to meet the needs of Advanced Drug Delivery Systems
1,2
. 
 
Polymers have been successfully investigated and employed in the 
formulation of solid, liquid and semi-solid dosage forms and are specifically useful in 
the design of novel drug delivery systems. Both synthetic and natural polymers have 
 
been investigated extensively for this purpose
3
. Synthetic polymers are toxic, 
expensive, have environment related issues, need long development time for synthesis 
and are freely available in comparison to naturally available polymers. However the 
use of natural polymers for pharmaceutical applications is fast increasing because 
they are economical, easily available, non toxic, capable of chemical modifications, 
biodegradable and biocompatible. 
 
A large number of plant-based pharmaceutical excipients are available today. 
Many researchers have explored the use fullness of plant-based materials as 
pharmaceutical Excipients. Due to their ability to produce a wide range of material 
based on their properties and molecular weight, natural polymers are used in majority 
of investigations in various drug delivery systems 
4
. The natural gums can also be 
modified based on their chemical structure to produce newer excipients that can meet 
the requirements of novel drug delivery systems which can competitive with synthetic 
excipients. 
 
1 
The plant based polymers have been studied for their application in different 
pharmaceutical dosage forms like matrix controlled systems, film coating agents, 
Nanoparticles, microspheres, buccal films, ophthalmic solutions, suspensions, 
 
implants and their applicability and efficiency has been proven
5-7
. They have also 
been utilized as stabilizers, viscosity enhancers, disintegrants, solubilizers, gelling 
 
agents, suspending agents in above mentioned dosage forms.
8 
 
Natural gums and mucilage are composed of many constituents. In several 
cases, the polysaccharides, resins or the tannins present in the gum are responsible for 
imparting release retard and properties to the dosage form. Gums are obtained from 
various parts of the plants. The source of the gums may be the epidermis, leaf, bark or 
roots or any other part of the plant. 
 
Gastro retentive drug delivery systems significantly improve therapeutic 
efficacy of drugs that act locally in stomach, drugs that have narrow absorption 
window in stomach or drugs that are unstable in the intestinal or colonic environment. 
Hydration and swelling ability of polymers are the key performers in gastro retentive 
drug delivery system or which various synthetic, natural and semi synthetic polymers 
materials have been investigated.
9
 many natural polymeric materials have been 
successfully used in formulation of gastro retentive drug delivery systems. These 
materials include: guar gum, is apghula husk, pectin, galactomannon from 
Mimosascabrella, Gleditsiatri acanthus Linn(honey locustgum),Sesbaniagum, 
mucilage from the pods of Hibiscusesculenta,Tamarindseed gum, Tara gum obtained 
from seed of Caesal piniaspinosa, okra gum obtained from pods Abelmoschusescu 
lentus, gum Karaya obtained from fruits of Streculiaurens etc. 
 
 
 
 
 
 
 
 
 
2 
1.1 Gastro Retentive Drug Delivery System 
 
Gastro retentive dosage forms are drug delivery systems which remain in the 
stomach for an extended period of time and allow both spatial and time control of 
drug liberation. Basically gastro retentive systems swells following ingestion and is 
retained in the stomach for a number of hours, while it continuously releases the 
incorporated drug at a controlled rate to preferred absorption sites in the upper 
intestinal tract. Their application can be advantageous in the case of drugs absorbed 
mainly from the upper part of GIT or are unstable in the medium of distal intestinal 
regions. They can also be used beneficially in the local therapy of the stomach. 
Prolonged gastric retention of the drugs may offer numerous advantages including 
improved bioavailability, therapeutic efficacy and possible reduction of dosage size. 
 
1.2 Gastrointestinal Tract 
 
1.2.1 Anatomy of the gastrointestinal tract: 
 
The gastrointestinal tract is divided into three main regions namely
9
: Stomach, 
Small intestine (Duodenum, Jejunum and Ileum) and large intestine. The GIT is a 
muscular tube, from the mouth to the anus, which functions to take in nutrients and 
eliminate waste by secretion, motility, digestion, absorption and excretion, which are 
known as physiological processes. The stomach is a J-shaped enlargement of the GIT 
which is divided into 4 anatomical regions: cardiac, fundus, body and antrum
10
 
(Fig.2.1). The main function of the stomach is to store and mix food with gastric 
secretions before emptying its load (chyme) through the pyloric sphincter and into the 
small intestine at a controlled rate suitable for digestion and absorption. During empty 
state, the stomach occupies a volume of about 50 ml, but this may increase to as much 
as 1 liter when full. The walls of the GIT, from stomach to large intestine, have the 
same basic arrangement of tissues, the different layers, from outside to inside, 
comprising serosa, intermuscular plane, longitudinal muscle, submucosa, circular 
 
3 
muscle, lamina propria, muscularis mucosae, and epithelium. In addition to 
longitudinal and circular muscle, the stomach has a third muscle layer known as the 
"oblique muscle layer", which is situated in the proximal stomach, branching over the 
fundus and higher regions of the gastric body. The different smooth muscle layers are 
responsible for performing the motor functions of the GIT, i.e. gastric emptying and 
intestinal transit. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1: Anatomy of the gastrointestinal tract 
 
1.2.2 Basic gastrointestinal tract physiology. 
 
The stomach is divided into 3 regions anatomically:fundus, body, and antrum 
pylorus. The proximal partis the fundus and the body acts as a reservoir forundigested 
material, where as the antrum is the mainsite for mixing motions and acts as a pump 
for gastric emptying by propelling actions. Gastric emptying occurs during fasting as 
well as fed states but the pattern of motility is distinct in the 2 states. During the 
fasting state an interdigestive series of electrical events take place, which cycle 
through both stomach and intestine every 2 to 3 hours. This is called the 
interdigestivemyloelectric cycle or migrating myloelectric cycle (MMC), which is 
divided into following 4 phases
10
 (fig.2.1). 
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Figure 1.2: Schematic representation of interdigestive motility 
 
 
 
 
 Phase I: This period lasts about 30 to 60 minutes with no contractions.

 Phase II: This period consists of intermittent contractions that increase 
gradually in intensity as the phase progresses, and it lasts about 20 to 40 
minutes. Gastric discharge of fluid and very small particles begins later in this 
phase.

 Phase III: This is a short period of intense distal and proximal gastric 
contractions (4-5 contractions per minute) lasting about 10 to 20minutes these 
contractions, also known as „„house-keeper wave,‟‟ sweep gastric contents 
down the small Intestine.

 Phase IV: This is a short transitory period of about 0 to 5 minutes, and the 
contractions dissipate between the last part of phase III and quiescence of 
phase I.
 
1.3 Need for gastroretention
10 
 
 Drugs that are absorbed from the proximal part of the gastrointestinal tract 
(GIT).

 Drugs that are less soluble or that degrade at the alkaline pH.

 Drugs that are absorbed due to variable gastric emptying time.
 
 
5 
 Local or sustained drug delivery to the stomach and proximal small intestine 
to treat certain conditions.

 Particularly useful for the treatment of gastric ulcers caused by H.Pylori 
infections.
 
1.4 Formulation considerations for GRDDS
11 
 
 It must be effective for retention in the stomach to suit the clinical demand.

 It must be convenient for intake to facilitate patient compliance.

 It must have sufficient drug loading capacity and control drug release profile.

 It must have full degradation and evacuation of the system once the drug 
release is over.

 It should not have effect on gastric motility including emptying pattern.

 It should not have other local adverse effects.
 
1.5 Certain types of drugs can benefit from using gastroretentive 
 
devices
12 
 
 Drugs acting locally in the stomach.

 Drugs those are primarily absorbed in the stomach.

 Drugs those are poorly soluble at an alkaline PH.

 Drugs with a narrow window of absorption.

 Drugs absorbed rapidly from the GI tract.

 Drugs those degrade in the colon.
 
1.6Drugs those are unsuitable for  Gastro retentive drug delivery 
 
systems
13 
 
 Drugs that have very limited acid solubility e.g. Phenytoin etc.

 Drugs that suffer instability in the gastric environment e.g. Erythromycin etc.
 
 
 
 
 
6 
 Drugs intended for selective release in the colon e.g. 5- amino salicylic acid 
and corticosteroids etc.
Drugs that are good candidates
14
  for GRDDS and some gastro retentive products 
 
 
available in market, are listed in table 2.1 and table 2.2respectively. 
 
 
 
 
 
 
Table 1.1: Good candidates for Gastro retentive Drug Delivery Systems 
 
 S.NO  Drug   Category  Half    Peak  Bioavailability 
            
life 
   
time(hrs
) 
   
                  
                     
 1    Atenolol   Antihypertensive    4    3   40-50%  
                     
                   
2    Clarithromycin   Antibiotic  3-4  2-2.5  50%  
                
               
 3    Diltiazem   Calcium channel    3-4.5    50min   40%  
        
blocker 
            
                    
                 
4    Lidocaine   Local anaesthetic  1.5-2  4  35%  
                
                     
               
 5    Nifedipine   Calcium channel    2    0.5-0.2   45-65%  
        
blocker 
            
                    
                 
6    Omeprazole   Proton pump  1-2  1  35-60%  
        
inhibitor 
          
                  
               
 7    Propranolol   Antihypertensive    4-5    4   26%  
                     
               
8    Ramipril   ACE inhibitor  2-4  3-5  28%  
                     
                     
              
9    Verapamil   Calcium channel   6   1-2  20-35%  
        
blocker 
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12, 15 
Table 1.2: Marketed formulations available as GRDDS 
 
 S.NO:  Brand Name   Drug(dose)  Company, Country   Remarks 
               
               
 1   AlmagateFlot   Al-Mg antacid      Floating dosage  
    
coat® 
     
---------- 
  
form. 
 
            
              
2   Cifran OD®   Ciprofloxacin  Ranbaxy, India   Gas generating 
       
(1gm) 
    
floating form.            
            
 3   Conviron®   Ferrous sulphate   Ranbaxy, India   Colloidal gel  
             
forming FDDS. 
 
              
             
4   Cytotech®   Misoprostol  Pharmacia, USA   Bilayer floating 
       
(100µg/200µg) 
    
capsule. 
           
           
            
 5   Liquid Gavison®   Al hydroxide (95   GlaxoSmithKline,   Effervescent  
       
mg), Mg 
  
India. 
  
floating liquid 
 
            
       
Carbonate (358 
     
alginate 
 
             
       mg)      preparations  
              
6   Madopar®HBS   Levodopa  Roche Products, USA   Floating CR 
    
(Propal® HBS) 
  
(100mg) 
    
capsules 
          
          
       
and Benserazide 
      
             
             
       (25mg)       
            
 7   Oflin OD®   Ofloxacin   Ranbaxy, India   Gas generating  
       
(400mg) 
     
floating tablet. 
 
             
              
8   Topalkan®   Al-Mg antacid  Pierre Fabre Drug,   Effervescent 
          
France 
  
floating liquid             
             
alginate              
             preparation. 
               
            
9   Valrelease®   Diazepam (15mg)  Hoffmann-LaRoche,   Floating Capsules 
          
USA 
    
              
               
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
8 
1.7 Various Factors affecting gastricretention
12 
 
Various factors that affect the bioavailability of dosage form and efficacy of the 
gastro retentive system are: 
 
 Density: Gastric retention time (GRT) is a function of buoyancy of dosage 
form that is dependent on the density.

 Size: Dosage form units with a diameter of more than 7.5 mm are reported to 
have an increased GRT compared with those with a diameter of 9.9 mm.

 Shape: Tetrahedron and ring shaped devices with a flexural modulus of 48 
and 22.5 kilo pounds per square inch (KSI) are reported to have better GRT 
90% to 100% retention at 24 hours compared with other shapes.

 Single or Multiple unit formulation: Multiple unit formulations show a more 
predictable release profile and insignificant impairing of performance due to 
failure of units, allow co-administration of units with different release profiles 
or containing incompatible substances and permit a larger margin of safety 
against dosage form failure compared with single unit dosage forms.

 Fed or unfed state: Under fasting conditions, the GI motility is characterized 
by periods of strong motor activity or the migrating myoelectric complexes 
(MMC) that occur are every 1.5 to 2hrs. The MMC sweeps undigested 
material from the stomach and, if the timing of administration of the 
formulation coincides with that of the MMC, the GRT of the unit can be 
expected to be very short. However, in the fed state, MMC is delayed and 
GRT is considerably longer.

 Nature of meal: Feeding of indigestible polymers or fatty acid salts can 
change the motility pattern of the stomach to a fed state, thus decreasing the 
gastric emptying rate and prolonging drug release.
 
 
 
9 
 Caloric content: GRT can be increased by 4 to 10 hours with a meal that is 
high in proteins and fats.

 Frequency of feed: The GRT can increase by over 400 minutes when 
successive meals are given compared with a single meal due to the low 
frequency of MMC.

 Gender: Mean ambulatory GRT in males (3.4±0.6 hours) is less compared 
with their age and race matched female counterparts (4.6±1.2 hours), 
regardless of the weight, height and body surface).

 Age: Elderly people, especially those over 70, have a significantly longer 
GRT.

 Posture: GRT can vary between supine and upright ambulatory states of the 
patient.

 Concomitant drug administration: Anticholinergics like atropine, 
propantheline, opiates like codeine and prokinetic agents like Metoclopramide 
and Cisapride can affect floating time.

 Biological factors: Diabetes and Crohn‟s disease etc.
 
1.8 Approaches to Gastric retention 
 
Various approaches for gastro retentive drug delivery systems are: 
 
Floating drug delivery 
 
Floating Drug Delivery Systems(FDDS) have a bulk density lower than gastric 
fluids and thus remain buoyant in the stomach
12
, (fig.2.3), for a prolonged period of 
time, without affecting the gastric emptying rate and the drug is released slowly at a 
desired rate from the system, results in an increase in the gastric residence time and a 
better control of fluctuations in the plasma drug concentrations and after complete 
release of the drug, the residual system is emptied from the stomach. 
 
 
 
10 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3: Graphic of the buoyant tablet which is less dense than the stomach 
 
fluid and therefore remains in the fundus. 
 
Bio/Muco-adhesive systems 
 
Bio/muco-adhesive systems, 
12
 bind to the gastric epithelial cell surface or 
mucin, which extends the GRT of drug delivery system in the stomach. The surface 
epithelial adhesive properties of mucin have been well recognized and applied to the 
development of GRDDS based on bio/muco-adhesive polymers. The ability to 
provide adhesion of a drug delivery system to the gastrointestinal wall provides 
longer residence time in a particular organ site, thereby producing an improved effect 
in terms of local action or systemic effect. Binding of polymers to the 
mucin/epithelial surface can be divided into three categories: 
 
1. Hydration-mediated adhesion: 
 
Certain hydrophilic polymers tend to imbibe large amount of water and 
become sticky, thereby acquiring bioadhesive properties. 
 
2. Bonding-mediated adhesion: 
 
The adhesion of polymers to a mucus/epithelial cell surface involves various 
bonding mechanisms, including physical-mechanical bonding and chemical bonding. 
Physical-mechanical bonds can result from the insertion of the adhesive material into 
the folds or crevices of the mucosa. Chemical bonds may be either covalent (primary) 
or ionic (secondary) in nature. Secondary chemical bonds consist of dispersive 
interactions (i.e., Vander Waals interactions) and stronger specific interactions such as 
 
11 
hydrogen bonds. The hydrophilic functional groups responsible for forming hydrogen 
bonds are the hydroxyl and carboxylic groups. 
 
3. Receptor-mediated adhesion: 
 
Certain polymers bind to specific receptor sites on the cell surfaces, thereby 
enhancing the gastric retention of dosage forms. Various investigators have proposed 
different mucin-polymer interactions, 
11
 such as: 
 
 Wetting and swelling of the polymer to permit intimate contact with the 
biological tissue.


 Interpenetration of bioadhesive polymer chains and entanglement of polymer 
and mucin chains.

 Formation of weak chemical bonds.
 Sufficient polymer mobility to allow spreading.
 Water transport followed by mucosal dehydration.
 
The bioadhesive coated system when comes in contact with the mucus layer, 
various non-specific (Vander Waals, hydrogen bonding and/or hydrophobic 
interactions) or specific interactions occurs between the complimentary structures and 
these interactions last only until the turnover process of mucin and the drug delivery 
system should release its drug contents during this limited adhesion time, in order for 
a bioadhesive system to be successful. 
 
Raft-forming systems: 
 
These systems, 
16
 contain gel-forming solution (e.g. sodium alginate solution 
containing carbonates or bicarbonates), which on contact with the gastric contents, 
swells and forms a viscous cohesive gel containing entrapped CO2 bubbles, releases 
drug slowly in stomach by forming the raft layer on the top of gastric fluid (fig.2.4). 
These formulations contain antacids such as calcium carbonate or aluminum 
hydroxide to reduce gastric acidity. 
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Figure 1.4: Barrier formed by a raft-forming system 
 
Low density systems: 
 
Low density systems, 
11
 (<1 g/cm3) which have immediate buoyancy have 
been developed because, the gas-generating systems have a lag time before floating 
on the stomach contents, during which the dosage form may undergo premature 
evacuation through the pyloric sphincter. These are made of low density materials, 
entrapping air or oil. Most of the low density systems are multiple unit systems, also 
called as „„microballoons‟‟ because of the low-density core (Sato and Kawashima, 
2004). The preparation of these hollow microspheres (fig.2.5), involves simple 
solvent evaporation or solvent diffusion methods. Polycarbonate, cellulose acetate, 
Eudragit S, calcium alginate, low methoxylated pectin and agar are commonly used as 
polymers. Drug release and buoyancy are dependent on the plasticizer-polymer ratio, 
quantity of polymer, and the solvent used. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5: Foam-particles 
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Swelling/Expanding/Unfoldable systems: 
 
A dosage form in the stomach will withstand gastric transit if it is bigger than 
the pyloric sphincter, also the dosage form must be small enough to be swallowed, 
and must not cause gastric obstruction either singly or by accumulation. Thus, their 
configurations are required to develop an expandable system in order to prolong the 
gastric retention time (GRT) 
16
: 
1) A small configuration for oral intake. 
 
2) An expanded gastroretentive form. 
 
3) A final small form enabling evacuation following drug release from the device. 
Thus, gastro retentivity is improved by the combination of substantial dimension with 
high rigidity of dosage form to withstand peristalsis and mechanical contractility of 
the stomach. Unfoldable and swellable systems have been investigated and recently 
tried to develop an effective gastroretentive drug delivery. 
 
 Unfoldable systems, 16 are made of biodegradable polymers. They are 
available in different geometric forms (fig.2.6), like tetrahedron, ring or 
planner membrane (4 - label disc or 4 - limbed cross form) of bioerodible 
polymer compressed within a capsule which extends in the stomach.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6: Different geometric forms of unfoldable systems. 
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 Swellable systems, 16(fig.2.7), are also retained in the gastro intestinal tract 
(GIT) due to their mechanical properties. The swelling is usually results from 
osmotic absorption of water and the dosage form is small enough to be 
swallowed by the gastric fluid.

 Expandable systems, 16 have some drawbacks like problematical storage of 
much easily hydrolysable, biodegradable polymers relatively short-lived 
mechanical shape memory for the unfolding system most difficult to 
industrialize and not cost effective. Again, permanent retention of rigid, large 
single-unit expandable drug delivery dosage forms may cause brief 
obstruction, intestinal adhesion and gastropathy.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.7: Drug release from swellable systems 
 
Superporous Hydrogels: 
 
Conventional hydrogels, with pore size ranging between 10 nm and 10 µm has 
very slow process of water absorption and require several hours to reach an 
equilibrium state during which premature evacuation of the dosage form may occur 
while the superporous hydrogel (fig.2.8), having average pore size (>100 µm), swell 
to equilibrium size within a minute, due to rapid water uptake by capillary wetting 
through numerous interconnected open pores. Moreover they swell to a large size 
(swelling ratio 100 or more) and are intended to have sufficient mechanical strength to 
withstand pressure by gastric contractions. This is achieved by a co- formulation of a 
hydrophilic particulate material, Ac-Di-Sol (crosscarmellose sodium) 
11
. 
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Figure 1.8: On the left, Superporous Hydrogels in its dry (a) and water-swollen 
 
(b) state. On the right, schematic illustration of the transit of Superporous 
 
Hydrogel. 
 
Magnetic systems: 
 
This approach is based on the simple principle that the dosage form contains a 
small internal magnet, and a magnet placed on the abdomen over the position of the 
stomach to enhance the gastric retention time (GRT) 
11
. The external magnet must be 
positioned with a degree of high precision that might compromise patient compliance. 
Self-unfolding systems: 
 
The self-unfolding systems are capable of mechanically increasing in size 
relative to the initial dimensions. This increase prevents the system from passing 
through the pylorus and retains for a prolonged period of time in the stomach. A drug 
can be either contained in a polymeric composition of the gastroretentive system or 
included as a separate component. Several methods, 
11
 were suggested to provide for 
the self-unfolding effect: 
1. The use of hydrogels swelling in contact with the gastric juice. 
 
2. Osmotic systems, comprising an osmotic medium in a semi-permeable  membrane. 
 
3. Systems based on low-boiling liquids converting into a gas at the body 
temperature. 
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i.)High density systems: 
 
These systems with a density of about 3 g/cm
3
 are retained in the rugae of the 
stomach and are capable of withstanding its peristaltic movements. A density of 
2.6-2.8 g/cm
3
 acts as a threshold value after which such systems can be retained 
in the lower part of the stomach. High density formulations include coated pellets. 
Coating is done by heavy inert material such as barium sulphate, zinc oxide, 
titanium dioxide, iron powder etc. They are retained in the antrum of stomach, 
12
 
(fig.2.9). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.9: Graphic of heavy tablet which is denser than the stomach fluid and 
 
therefore sinks to the antrum 
 
1.9 Floating drug delivery systems: 
 
A floating dosage form is useful for drugs acting locally in the proximal 
gastrointestinal tract. These systems are also useful for drugs that are poorly soluble 
(or) unstable in intestinal fluids. The floating properties of these systems help to retain 
in the stomach for a long time. Various attempts have been made to develop floating 
systems, which float on the gastric contents and release drug molecules for the desired 
time period. After the release of a drug, the remnants of the system are emptied from 
the stomach. 
 
Based on the mechanism of buoyancy, two different technologies have been 
used in development of floating drug delivery systems. These include: 
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a) Effervescent system. 
 
b) Non- Effervescent system. 
 
a) Effervescent Systems 
 
Effervescent systems,
12
 include use of gas generating agents, carbonates (e.g. 
Sodium bicarbonate) and other organic acid (e.g. citric acid and tartaric acid) present 
in the formulation to produce carbon dioxide (CO2) gas, thus reducing the density of 
the system and making it float on the gastric fluid. An alternative is the incorporation 
of matrix containing portion of liquid, which produce gas that evaporate at body 
temperature. 
 
These effervescent systems further classified into two types: 
 
1) Gas generating systems. 
 
2) Volatile liquid or vacuum containing systems. 
 
1) Gas generating systems 
 
a) Tablets: 
 
i. Intragastric single layer floating tablets or Hydrodynamically Balanced 
 
System 
 
These formulations have bulk density lower than gastric fluids and thus float in the 
stomach that increases the gastric emptying rate for a prolonged period,
12
 (fig.2.10). 
These are formulated by intimately mixing the gas (CO2) generating agents and the 
drug within the matrix tablet. The drug is released slowly at a desired rate from the 
floating system and the residual system is emptied from the stomach after the 
complete release of the drug. This leads to an increase in the gastric residence time 
(GRT) and a better control over fluctuations in plasma drug concentration. 
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Figure 1.10: Intragastric single layer floating tablet 
 
ii. Intragastric bilayer floating tablets 
 
These are also compressed tablets, 
12
 containing two layers (fig.2.11): 
 
 Immediate release layer and

 Sustained release layer. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.11: Intragastric bilayer floating tablet. 
 
b) Floating capsules 
 
These floating capsules, 
11
 are formulated by filling with a mixture of sodium 
alginate and sodium bicarbonate. The systems float as a result of the generation of 
CO2 that was trapped in the hydrating gel network on exposure to an acidic 
 
environment. 
 
c) Multiple unit type floating pills 
 
These multiple unit type floating pills, 
12
 are sustained release pills, known as 
„seeds‟, which are surrounded by two layers (fig.2.12). The outer layer is of swellable 
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membrane layer while the inner layer consists of effervescent agents. This system 
sinks at once and then it forms swollen pills like balloons which float as they have 
lower density, when it is immersed in the dissolution medium at body temperature. 
The lower density is due to generation and entrapment of CO2 within the system. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.12: (a) A multiple-unit oral floating dosage system. (b) Stages of floating 
mechanism: (A) penetration of water; (B) generation of CO2 and floating; (C) 
dissolution of drug. Key: (a) conventional SR pills; (b) effervescent layer; (c) 
swellable layer; (d) expanded swellable membrane layer; (e) surface of water in 
the beaker (37
0
C). 
d) Floating system with Ion-Exchange resins 
 
Floating system using bicarbonate loaded ion exchange resin was made by 
mixing the beads with 1M sodium bicarbonate solution, and then the semi-permeable 
membrane is used to surround the loaded beads to avoid sudden loss of CO2. On 
contact with gastric contents an exchange of bicarbonate and chloride ions takes place 
that results in generation of CO2 that carries beads towards the top of gastric contents 
and producing a floating layer of resin beads
11. 
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2) Volatile liquid or vacuum containing systems 
 
a) Intragastric floating gastrointestinal drug delivery system 
 
This system floats in the stomach because of floatation chamber, which is vacuum or 
filled with a harmless gas or air, while the drug reservoir is encapsulated by a 
microporous compartment, 
12
 (fig.2.1). 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.13: Intragastric floating gastrointestinal drug delivery device 
 
b)  Inflatable gastrointestinal delivery systems 
 
These systems are incorporated with an inflatable chamber, which contains liquid 
ether that gasifies at body temperature to inflate the chamber in the stomach. These 
systems are fabricated by loading the inflatable chamber with a drug reservoir, which 
can be a drug, impregnated polymeric matrix, then encapsulated in a gelatin capsule, 
12
 (fig.2.14). After oral administration, the capsule dissolves to release the drug 
reservoir together with the inflatable chamber. The inflatable chamber automatically 
inflates and retains the drug reservoir compartment in the stomach. The drug is 
released continuously from the reservoir into gastric fluid. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.14: Inflatable gastrointestinal delivery system 
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c) Intragastricosmotically controlled drug delivery system 
 
This system is comprised of an osmotic pressure controlled drug delivery device 
and an inflatable floating support in a biodegradable capsule, 
12
 (fig.2.15). On contact 
with the gastric contents in the stomach, the capsule disintegrates quickly to release 
the intra gastric osmotically controlled drug delivery device. The inflatable support 
inside forms a hollow polymeric bag which contains a liquid that gasifies at body 
temperature to inflate the bag and it is deformable. 
 
The osmotic pressure controlled drug delivery device consists of two 
components, osmotically active compartment and a drug reservoir compartment. The 
drug reservoir compartment is enclosed by a pressure responsive collapsible bag, 
which is impermeable to liquid and vapor and has a drug delivery orifice. The 
osmotically active compartment contains an osmotically active salt and is enclosed 
within a semi-permeable housing. 
 
In the stomach, the osmotically active salt present in the osmotically active 
compartment is dissolved by absorbing the water continuously present in the GI fluid 
through the semi-permeable membrane. An osmotic pressure is thus created which 
acts on the collapsible bag and in turn forces the drug reservoir compartment to 
reduce its volume and activate the drug reservoir compartment to reduce its volume 
and activate the drug release of a drug solution formulation through the delivery 
orifice. The floating support is also made to contain a bioerodible plug that erodes 
after a predetermined time to deflate the support. The deflated drug delivery system is 
then emptied from the stomach. 
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Figure 1.15: Intragastricosmotically controlled drug delivery system 
 
b) Non-Effervescent systems 
 
The Non-Effervescent floating drug delivery systems are based on mechanism 
of swelling of polymer or bioadhesion to mucosal layer in GI tract. The various types 
of this system are: 
 
1. Single layer floating tablets 
 
These are formulated by intimate mixing of drug with a gel forming 
hydrocolloid, that swells on contact with gastric fluid and maintain bulk density of 
less than unity. The air trapped by the swollen polymer confers buoyancy to these 
dosage forms
12
. 
2. Bilayer floating tablets 
 
A bilayer tablet contain two layer one immediate release layer which release 
initial dose from system while the another sustained release layer absorbs gastric 
fluid, forming an impermeable colloidal gel barrier on its surface, and maintain a bulk 
density of less than unity and thereby it remains buoyant in the stomach
12
. 
3. Alginate beads 
 
Multi unit floating dosage forms were developed from freeze dried calcium 
alginate. Spherical beads of approximately 2.5 mm diameter can be prepared by 
dropping a sodium alginate solution into aqueous solution of cacl2, causing 
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precipitation of calcium alginate leading to formation of porous system, which can 
maintain a floating force for over 12 hours. When compared with solid beads, which 
gave ashort residence, time of 1 hr, and these floating beads gave a prolonged 
residence time of more than 5.5 hours
12
. 
4. Hollow microspheres 
 
Hollow microspheres (microballons), loaded with drug in their outer polymer 
shells were prepared by a novel emulsion-solvent diffusion method (fig.2.16). The 
ethanol: dichloromethane solution of the drug and an enteric acrylic polymer was 
poured into an agitated aqueous solution of PVA that was thermally controlled at 
40
0
C. The gas phase generated in dispersed polymer droplet by evaporation of 
dichloromethane formed an internal cavity in microsphere of polymer with drug. The 
microballons floated continuously over the surface of acidic dissolution media 
containing surfactant for more than 12 hours in vitro
12
. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.16: Formulation of floating hollow microsphere or microballoon. 
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1.10 Advantages of floating drug delivery system
12 
 
 The principle of Hydro dynamically Balanced System (HBS) can be used for 
any particular medicament or class of medicament. The HBS formulations are 
not restricted to medicaments, which are principally absorbed from the 
stomach, since it has been found that these are equally efficacious with 
medicaments which are absorbed from the intestine. E.g. Chlorpheniramine 
maleate.

 The HBS are advantageous for drugs absorbed through the stomach e.g. 
ferrous salts and for drugs meant for local action in the stomach and treatment 
of peptic ulcer disease e.g. antacids.

 Administration of a prolonged release floating dosage form tablet or capsule 
will result in dissolution of the drug in gastric fluid. After emptying of the 
stomach contents, the dissolved drug is available for absorption in the small 
intestine, therefore it is expected that a drug will be fully absorbed from the 
floating dosage form if it remains in solution form even at alkaline p
H
 of the 
intestine.

 Many drugs categorized as once-a-day delivery have been demonstrated 
tohave suboptimal absorption due to dependence on the transit time of the 
dosage form, making traditional extended release development challenging. 
Therefore, a system designed for longer gastric retention will extend the time 
within which drug absorption can occur in the small intestine.

 When there is vigorous intestinal movement and a short transit time as might 
occur in certain type of diarrhoea, poor absorption isexpected under such 
circumstances it may be advantageous to keep the drug in floating condition in 
stomach to get a relatively better response.
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1.11 Limitations of floating drug delivery system
18 
 
 The floating system requires, sufficiently high level of fluid in the stomach for 
the system to float, this can be overcome by administering dosage form with a 
glass full of water (200-250 ml) or coating the dosage form with bioadhesive 
polymer which adhere to gastric mucosa.

 Aspirin and non steroidal anti-inflammatory drugs are known to cause gastric 
lesions, and slow release of such drugs in the stomach is unwanted.

 Drugs, such as Isosorbidedinitrate, that are absorbed equally throughout the GI 
tract, drugs undergoing first pass metabolism will not benefit from 
incorporation into a gastric retention system.

 Floating dosage form should not be given to the patients just before going to 
the bed as gastric emptying occurs rapidly when the subject remains in supine 
posture.

 Drugs that have stability or solubility problem in gastrointestinal fluid or that 
irritate gastric mucosa are not suitable.

 Drugs that have multiple absorption sites or which undergo first pass 
metabolism were not desirable.

 The single unit floating dosage form is associated with “all or none concept”.

This problem can be overcome by formulating multiple unit system like 
floating microballons or microspheres. 
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1.12Applications of floating drug delivery system
18 
 
1) Sustained drug delivery 
 
Hydrodynamically Balanced System (HBS) type dosage forms which have 
 
bulk density less than one, relatively large in size and did not easily pass through 
pylorus, release the drug over a prolonged period of time by retaining in the 
stomach for several hours and by increasing the gastric residence time. 
MadoparHBS formulation has shown torelease levodopa for up to 8 hour in vitro, 
whereas the standard formulation released levodopa in less than 30 min. 
 
2) Site specific drug delivery 
 
Floating drug delivery systems are particularly useful for drugs having specific 
 
absorption from stomach or proximal part of the small intestine e.g. riboflavin, 
furosemide etc. The absorption of Captopril has been found to be site specific, 
stomach being the major site followed by duodenum. This property prompts the 
development of a monolithic floating dosage form of Captopril which prolongs 
the gastric residence time and thus increases the bioavailability, which has shown 
AUC, approximately 1.8 times than that of conventional tablets. 
 
3) Absorption enhancement 
 
Drugs that have  poor bioavailability, because of their absorption  is  restricted 
 
to upper GIT are potential candidates to be formulated as floating drug delivery 
systems, thereby improving their absolute bioavailability. 
 
4) Minimized adverse activity at the colon 
 
Retention of the drug at the stomach (HBS system), minimizes the amount of 
 
drug that reaches the colon, that prevents the undesirable activities of the drug in 
colon. This Pharmacodynamic aspect provides the rationale for GRDF 
formulation for betalactam antibiotics that are absorbed only from the small 
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intestine, and whose presence in the colon leads to the development of 
microorganism‟s resistance. 
 
5) There are some cases in where the relative bioavailability of floating dosage 
form is reduced as compared to conventional dosage form e.g. floating tablets of 
amoxicillin trihydrate has bioavailability reduced to 80.5% when compared with 
 
conventional capsules. In such cases, the reduction in bioavailability is 
compensated by the advantages offered by FDDS e.g. patients with advanced 
Parkinson‟s disease, experienced pronounced fluctuations in symptoms while 
treatment with standard L-dopa. A HBS dosage form provided a better control of 
motor fluctuations although its bioavailability was reduced by 50-60% of the 
standard formulation. 
 
6) Helicobacter Pylori, causative bacterium for peptic ulcers and chronic gastritis. 
Patients require high concentration of drug, to be maintained at the site of 
infection that is within the gastric mucosa. The floating dosage form due to its 
floating ability was retained in stomach and maintained high concentration of drug 
in the stomach. A sustained liquid preparation of Ampicillin, using sodium 
alginate was developed that spreads out and adheres to gastric mucosal surfaces 
and releases the drug continuously. 
 
7) Floating drug delivery systems are particularly useful for drugs which are 
poorly soluble or unstable in intestinal fluids and acid stable drugs and for those 
which undergo abrupt changes in their pH-dependent solubility due to 
pathophysiological conditions of GIT, food and age, e.g. floating system for 
 
furosemide lead to potential treatment of Parkinson‟s disease. Approximate 30% 
drug was absorbed after oral administration. 
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1.13  Drug  release  Control  and  Mechanism  in  Swellable  Matrix 
 
tablets. 
 
1.13.1) Water penetration, swelling of matrix and gel layer formation 
 
Dynamics: 
 
Swellable matrix tablets are activated by water and drug release mechanism 
depends on interaction between water, polymer and drug. The first step involved is 
water penetration in to matrix leading to polymer swelling and polymer and drug 
dissolution. In presence of water the glass rubber, transition temperature is decreased 
which results in formation of rubbery gel layer from glassy polymer. The polymer 
relaxation phenomenon determines the swelling or volume increased in the matrix 
tablet. 
 
The thickness of gel layer formed depends on extent of water penetration, chain 
disentanglement and mass (polymer and drug) transfer in the water. Initially the water 
penetration is more rapid than chain disentanglement leading to quicker build up of 
gel layer, but later when water penetration is slow a little change in gel layer thickness 
is observed because water penetration and chain disentanglement rates are similar
19.
 
The gel layer thickness dynamics in swellable matrix tablets shows different three 
regions
20
: 
a) Initially it increases when water penetration is fastest phenomenon. 
 
b) Stays constant when rates of water penetration and chain disentanglement 
rates are similar. 
 
c) Decreases when the entire polymer converts to rubbery phase. 
 
The gel layer formed should prevent the matrix erosion and control additional water 
penetration. The factors influencing gel layer formation and drug release are water 
penetration, polymer swelling, drug dissolution and diffusion, and matrix erosion. 
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1.13.2 Boundaries of gel layer and relevant fronts: 
 
The boundaries of gel layer correspond to the fronts separating different matrix 
phases. The dynamics of gel layer formed is determined by the movements of 
different fronts. In swellable matrix tablets the following three fronts can be presented 
by same time: 
 
a) The swelling front which is the boundary layer between glassy polymer and 
rubbery polymer. 
 
b) The diffusion front which is the boundary between undissolved drug and 
dissolved drug in the gel layer. 
 
c) The erosion front which is the boundary between matrix and dissolution 
medium. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 1.17 Relative fronts of Swellable matrix tablet during drug release 
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1.13.3 Swelling behavior front movements and drug release: 
 
Due to dependence of gel layer thickness on the movement of swelling, 
diffusion and erosion fronts the analysis of front movement is use to interpret drug 
release in relation to swelling. The kinetics of drug release depends on the relative 
positions of erosion and swelling or diffusion forms. The rate of drug delivery is also 
dependent on the velocity of diffusion fronts. The drug release rate is inversely 
proportional to the dynamics of dissolved drug gel layer thickness. In swellable 
matrix tablets the erosion front movement determines the kinetics and diffusion front 
movement determines rate of drug release.Ritger and Peppas
21
 proposed an equation 
to describe drug release kinetics from swelling controlled drug delivery system. The 
equation is as follows: 
= ktn 
 
∞ 
 
Where Mt is drug released at time t, 
 
M∞ is amount of drug released at infinite time, 
 
K is kinetic constant, 
 
N is diffusion exponent. 
 
 
 
Table: 1.3. Drug release mechanisms from swelling controlled systems 
based on sample Geometry. 
 ‘n’ value (Diffusional exponent)  Transport Mechanism 
          
 Plane sheet   Cylinder   Sphere   
          
0.5  0.45  0.43  Fickian 
       
 >0.5   >0.45   >0.43  Anomalous 
          
<1.0  <0.89  <0.85  Anomalous 
       
 1.0   0.89   0.85  Case II 
          
>1.0  >0.89  >0.85  Super case II 
          
 
 
 
31 
REFERENCES 
 
1. RaymondCR, (Ed.), Handbook of Pharmaceutical Excipients. 5th ed. London 
(UK): The Pharmaceutical Press; 2006. 
 
2. PatelDM,. Seed mucilage from Ocimum americanumlinn. As disintegration 
tablets: Separation and evaluation. Indian JPharmSci 2007; 69:431-35. 
 
3. VarshosazJ, TavakoliN, EramSA. Use of naturalgums and cellulose 
derivatives in production of sustained release dosage forms. Drug Deliv 2006; 
13: 113-119. 
 
4. Banker GS, Anderson NR. Tablets. In: LachmanL, Lieberman HA,KanigJL. 
(Ed.), the theory and practice of industrialpharmacy .3rd Ed., Mumbai: 
Varghese Publishinghouse; 1987.336. 
 
5. PandeyR, Khuller GK. Polymer based drug delivery systems for 
mycobacterial infections.CurrDrugDeliv 2004; 1:195-201. 
 
6. Chamarthy S.P.,Pinal R. Plasticizer concentration and the performance of a 
diffusion controlled polymeric drug delivery system. Colloids surf.A. Physio 
chem.Eng Asp 2008; 331: 25 -30 
 
7. Alonso MJ. Glucomannan, A promising polysaccharide for 
Biopharmaceutical purposes.EurJ PharmBiopharm2009; 72(2): 453-62. 
 
8. GuoJ, Skinner GW, Pharmaceutical applications of naturally occurring water-
soluble polymers. Pharm S ci Technol Toda y1998; 1:254-61. 
 
9. Morkhade DM, Fulzele SV, Satturwar PM, Joshi SB. Gum Copaland Gum 
Damar: Novel Matrix Forming Materials for Sustained Drug Delivery. 
IndianJPharm Sci 2006; 68(1):53-58. 
 
10. S.U. Zate, P.I. Kothawade, “Gastroretentive Bioadhesive Drug Delivery 
System: A Review”, International Journal of Pharm Tech Research Res, 
2010, 2(2): 1227-1235. 
 
32 
11. Vinod K.R., Santhosh Vasa, Anbuazaghan S, David Banji1, Padmasri A, 
 
Sandhya  S,“Approaches  for  Gastroretentive  Drug  Delivery  Systems”, 
 
2010;1(2): 589-601. 
 
12. Debjit Bhowmik, Chiranjib. B. Jayakar, K.P.Sampath Kumar, “Floating Drug 
Delivery System: A Review”, Der Pharmacia Lettre, 2009, 1(2), 199-218. 
 
13. Amit KumarNayak, RumaMaji, Biswarup Das,“Gastroretentivedrug delivery 
systems: A review”, 2010, 3(1), 2-10. 
 
14. Praveen NASA, Sheefali Mahant, Deepika Sharma. Floating Systems, “A 
Novel Approach towards Gastroretentive Drug Delivery Systems”, Int J 
Pharmacy and Pharm Sci, 2010,2(3), 2-7. 
 
15. S. B. Gholap, S. K. Banarjee, R. M. Thorat,“Hollow Microsphere: A 
Review”, 2010,1(1), 74-79. 
 
16. Hetangi Rathod, Vishnu Patel, Moin Modasia, “Floating Drug Delivery 
System: Innovative Approach of Gastroretention”, 2010, 4(3) 183-192. 
 
17. ShwetaArora, Javed Ali, AlkaAhuja, Floating Drug Delivery Systems: A 
Review”, AAPS PharmSciTech, 2005, 6 (3), 372-390. 
 
18. Singh Sanjay, Joshi Vaibhav, and BarpetePravin Kumar,“Gastroretentive 
Drug Delivery System: Current Approaches”, Journal of Pharmacy Research, 
2009; vol 2(5): 881-886. 
 
19. Lee, P.I. Controlled drug release from polymeric matrices involving moving 
boundaries, In: D.H. Levis (Ed), Controlled release of pesticides and 
pharmaceuticals 1981. Plenum publishing,NewYork. 39-48. 
 
20. Harland R.S., Gazzaniga A, Peppas N.A. etal. Drug /Polymer matrix swelling 
and dissolution. Pharm res 1988; vol 5: 488-494. 
 
21. Ritger P.L. ,Peppas. A simple equation for description of solute release. II 
 
.Fickian andanomalous release from swellable devices. JCR 1987; 5: 37-42 
 
 
 
33 
 2. DRUG AND POLYMER PROFILE 
 
2.1 LEVOFLOXACIN HEMIHYDRATE
1
. 
 
Molecular Formula:C18H20FN3O4 
 
Chemical Structure:  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(2S)-7-fluoro-2-methyl-6-(4-methylpiperazin-1-yl)-10-oxo-4-oxa-1- 
 
azatricyclo[7.3.1.0^{5,13}]trideca-5(13),6,8,11-tetraene-11-carboxylic acid 
 
Molecular Weight:361.368 
 
Drug Category: 
 
 Anti-bacterial agent.

 Nucleic acid synthesis inhibitor.

 Anti infective agent.
 
Description: Stable, yellowish amorphous powder. 
 
Solubility: Readily soluble in water (25mg/ml) 
 
Melting Point: 163-164
0
C. 
 
Mechanism of Action: 
 
Levofloxacin inhibits bacterial type II topoisomerases, topoisomerase IV and 
DNA gyrase. Levofloxacin, like other fluoroquinolones, inhibits the A subunits of 
DNA gyrase, two subunits encoded by the gyrA gene. This results in strand breakage 
on a bacterial chromosome, super coiling, and resealing, DNA replication and 
transcription is inhibited. 
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Pharmacokinetic profile of Levofloxacin 
 
 Absorption: Levofloxacin is rapidly and, in essence, completely absorbed 
after oral administration. The amount of drug absorbed increases 
proportionately with the dose.

 Peak plasmaconcentration: Occurs 2 hours after oral administration.

 Protein binding: 24-38% (to plasma proteins).

 Metabolism: Mainly excreted as unchanged drug (87%); undergoes limited 
metabolism in humans. metabolism occurs by glucuronidation and 
hydroxylation.

 Route of elimination: Mainly excreted as unchanged drug in the urine.

 Half life: 6 hours.
 
Pharmacology 
 
Levofloxacin is the L-isomer of the racemate ofloxacin, a quinolone 
antimicrobial agent. In chemical terms Levofloxacin, a chiral fluorinated 
carboxyquinolone, is the pure (-)-(S)-enantiomer of the racemic drug substance 
Ofloxacin. 
 
Dose: Levofloxacin is used in doses of 250mg, 500mg and 750mg. 
 
Therapeutic uses: 
 
Levofloxacin is used in treatment of the following: 
 
 Respiratory tract infections.

 Urinary tract infections.

 Anthrax

 Meningitis

 Helicobacter pylori infections.
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Contraindications: 
 
Levofloxacin hemihydrate is contraindicated in: 
 
 Hepatic diseases.

 Pregnancy.

 Epilepsy.

 Arthritis, Arthralgia in case of children.
 
Drug Interactions: 
 
 Caffeine: Metabolism affected by inhibiting cytochrome P-450.

 NSAID‟S: Severe CNS adverse reactions.

 Corticosteroids:  Increased risk of Achilles tendon rupture.

 Concomitant use with cardiac antidysrhythmics: Increased risk of torsades and 
R on T syndrome.

 Quinidine barbiturates: Increased risk of cardio toxicity and arrhythmias.

 Warfarin: Levofloxacin may increase the anticoagulant effect of warfarin.

 Iron: Levofloxacin forms insoluble complexes with iron.

 Levofloxacin on coadminstration with orange juice can reduce the plasma 
quinoline levels.
 
Adverse Effects: 
 
 Hypersensitivity.

 Peripheral neuropathy.

 Acute pancreatitis.

 Auto immune hemolytic anemia.

 Corneal perforation.

 Stevens-Johnson s
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2.2. HYDROXYL PROPYL METHYL CELLULOSE (HPMC) 
2 
 
Synonym: 
 
Hypromellose, Hydroxyl propyl methyl cellulose,Methocel, Methyl cellulose 
propylene glycol ether, Metolose, Tylopur. 
 
Chemical name: 
 
Cellulose hydroxyl propyl methyl ether 
 
Description: 
 
Metolose is a white to slightly off-white powder and practically odorless 
and tasteless. 
 
Solubility: 
 
It is soluble in cold water, forming a viscous colloidal solution, practically 
insoluble in chloroform, ethanol, but soluble in mixtures of ethanol and 
dichloromethane. 
 
Functional Category 
 
 Coating agent.

 Film-former.

 Rate-controlling polymer.

 Stabilizing agent.

 Suspending agent.

 Tablet binder.

 Viscosity increasing agent.
 
Applications 
 
 Hypromellose is used in oral, ophthalmic and topical pharmaceutical 
formulations.
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 In oral products hypromellose is used as a tablet binder, in film coating and as 
a matrix for use in extended release tablet formulations.

 Hypromellose is also used as a suspending and thickening agent in topical 
formulations.
 
2.3.GUM KARAYA 
3,4 
 
Source: 
 
Gum Karaya, sometimes known as Sterculia gum, is the dried exudation of the 
Sterculia Urens tree and other species of Sterculia and belong to Sterculiaceae family. 
The tree is native to India. 
 
Description: 
 
The highest grade sorts of Gum Karaya are white, translucent and almost free 
of bark. Powdered Gum Karaya is white to greyish white. 
 
Solubility: 
 
Powdered gum karaya swells in cold water to an extent that a 3% to 4% sol 
will produce a heavy gel of uniform smoothness and texture. 
 
Chemical Constituents: 
 
Gum Karaya is a complex polysaccharide of high molecular weight. A 
molecular weight as high as 9.500.000 has been reported. On hydrolysis it yields 
galactose, rhamnose and galacturonic acid. Gum Karaya occurs as a partially 
acetylated derivative. Gum Karaya contains 12% to 14% moisture and less than 1% 
acid insoluble ash. 
 
pH: 
 
The pH of a 1% Gum Karaya solution is 4.6. If small amounts of alkali are 
added to change the pH to 7 or 8, the gum tends to have a buffering action effect and 
will gradually reduce the pH again to the acid size. 
 
Pharmaceutical Applications: 
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A large part of the Karaya is used in two products. In the first product, bulk 
laxative, Karaya is usually processed 8-30mesh in size. In absorbing water the coarse 
particles swell enormously, forming a discontinuous type of mucilage that is very 
effective as a laxative. The second important product is a denture adhesive in which 
the finely powdered gum is dusted on the dental plate and swells when it touches the 
moist surface of the gums. This gives a comfortable and tight fit of the plate. 
 
2.4. GUM KONDAGOGU 
5 
 
Source: 
 
It is natural gum exudates, obtained from stems and branches of 
“Cochlospermum gossypium” and belongs to Bixaceae family. Description: It occurs 
as pale brown to brown in colour. 
 
Solubility: It is swellable in water. 
 
pH: 
 
The pH of 1 %w/v gum solution ranged from 4.9 to 5.1. 
 
Chemical Constituents: 
 
It Consists of high molecular weight acetylated polysaccharides, which on 
hydrolysis yield galactose, rhamnose, and galacturonic acid, together with minor 
amounts of glucuronic acid. 
 
Pharmaceutical Applications: 
 
Gum is sweet, cooling and useful in diarrhoea, dysentery, cough, pharyngitis, 
and also used as a pharmaceutical aid. Gum kondagogu was used as a substitute for 
gum tragacanth. Gum kondagogu is used as a drug delivery biopolymer and nano-
composite material for removal of toxic metals. 
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2.5. XANTHAN GUM
6
: 
 
Source: 
 
It is obtained by fermentation of glucose,sucrose or lactose by using 
Xanthomonas campestris bacterium. 
 
Description: 
 
Pale to off-white colored powder 
 
Solubility: 
 
Highly soluble in cold and hot water 
 
Chemical composition: 
 
Chemically, Xanthan gum is a polysaccharide composed of the sugars 
galactose and mannose. The backbone is a linear chain of β 1,4-linked mannose 
residues to which galactose residues are 1,6-linked at every second mannose, forming 
short side-branches. 
 
Applications in Pharmaceutical Formulation 
 
It is used in controlled release and sustained release formulations as matrix 
former. 
 
1. Used as a thickening agent and stabilizing agent in emulsions. 
 
2. In cosmetics, it is used to prepare water gels, usually in conjunction with 
bentonite clays. 
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2.6. NEEM GUM
7 
 
Source: 
 
Neem gum is the bark extract of the plant Azadirachta indica. It is purified by 
dissolving it in cold water followed by precipitation with ethanol. Family: Meliaceae 
 
Description: 
 
Neem gum is clear bright amber coloredmaterial which on extraction with 
 
ethanol gives white amorphous powder. 
 
Solubility: Readily soluble in cold water. 
 
Chemical composition: 
 
Neem gum is composed of three bitter agents‟ nimbin, nimbinin and nimbidin. 
 
These are chemically triterpinoids. 
 
Applications in Pharmaceutical Formulation 
 
1. Binding agent in tablet formulations. 
 
2. Used as stabilizing and thickening agent in jells. 
 
3. Used in formulation of antiseptic creams. 
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 3. LITERATURE REVIEW 
 
3.1. PAST STUDIES ON FLOATING DRUG  DELIVERY SYSTEMS OF 
 
LEVOFLOXACIN HEMIHYDRATE. 
 
 Thakkar V.T et al.,2008 formulated and evaluated Levofloxacin hemihydrate 
floating tablets using Gelurice and Methocel HPMC K4M. As the


concentration of HPMC was increased the floating lag time was found to 
decrease and as concentration of Gelurice was increased the drug release rate 
decreased. The release rate of Levofloxacin hemihydrates was mainly 
governed by the hydrophilic and the hydrophobic polymer ratio. Formulations 
containing 25% HPMC and 15% Gelurice showed controlled release and good 
floating behavior. Optimal batch was found by regression analysis which 
followed Higuchi kinetics. 

 Arunachalam. Aet al., 2010 formulated floating effervescent floating tablets 
of Levofloxacin hemihydrate employing melt granulation using bees wax,


HPMC K4M and Ethyl cellulose. Sodium bicarbonate was used as gas 
generating agent. Bees wax is selected to provide hydrophobic melt able 

support to give sufficient integrity to tablets.Formulations containing higher 
amount of bees wax F6-F7 showed less than 80% of drug release in 12 hours. 
As the concentration of bees wax was increased the release of Levofloxacin 
was sustained. 

 Shreeraj H. Shah et al.,2010 formulated floating tablets of Levofloxacin 
hemihydrate for treating Helicobacter pylori infections using combinations of


different viscosity grades of Hpmc and carbopol by wet granulation employing 
PVP-k30M as binder. The combination of polymers showed good 
swellabilityand HPMC K4M when used alone showed good floating lag time. 
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They compared the drug release profile of formulated product with marketed 
product and established that formulated product showed better controlled 
release rate. 
 
 Nagesh C et al.,2011formulated floating microspheres of Levofloxacin 
hemihydrates employing emulsion solvent evaporation technique. The drug


was encapsulated in HPMC and Eudragit S 100 in different polymer ratios i.e. 
1:1, 1:2, 1:3. The % yield of microspheres was higher with HPMC than 
Eudragit S 100 and the particle size of microspheres increased with an increase 
in increase in polymer concentration. From the percentage buoyancy studies of 
microspheres it was found that the microspheres remain buoyant in buffer for 
more than 12 hours. Microspheresof Levofloxacin formulated with HPMC 
showed enhanced release rate when compared to microspheres with Eudragit S 
100. 
 
3.2 PAST STUDIES ON FLOATING DRUG DELIVERY SYSTEMS OF 
 
XANTHAN GUM. 
 
 Brijesh S. Dave et al.,2004 prepared and evaluated gastro retentive drug 
delivery system of ranitidine hydrochloride. Guar gum, xanthan gum, and


hydroxyl propyl methylcellulose were evaluated for gel-forming properties. 
The times required for 50% (t50) and 80% drug dissolution (t80), and the 
similarity factor f2 were selected as dependent variables. The results of the full 
factorial design indicated that a low amount of citric acid and a high amount 
of stearic acid favors sustained release of ranitidine hydrochloride from a 
gastroretentive formulation. 

 Viral F. Patel et al.,2007 studied influence of xanthan gum and guar gum 
blends on dipyridamole release from floating matrix tablets. The content of


polymer blends (X1) and ratio of xanthan gum to guar gum (X2) were selected 
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as independent variables. The diffusion exponent (n), release rate constant (k), 
percentage drug release at 1 hr (Q1) and 6 hr (Q6) were selected as dependent 
variables. Tablets of all batches had desired buoyancy characteristics. Multiple 
regression analysis with two ways ANOVA revealed that both the factors had 
statistically significant influence on the response studied (p < 0.05). Results of 
Tukey testshowed the relative contribution of each level of different factors for 
the response studied. It was concluded that the ratio of xanthan to gaur gum 
had equal or dominant role as controlling factor on kinetics of drug release 
compared to content of polymer blends. 
 
 Rajeev das et al., 2009 used Sylimarin as model drug to prepare gastro 
retentive floating tablets employing Xanthan gum. . In-vitro drug release


studies were performed and drug release kinetics were evaluated by Linear 
regression method and the formulations followed both Peppas and Higuchi 
equations. The drug release mechanism was found to follow Fickian type in 
most of the formulations. The formulated floating tablets prolonged the drug 
release for 24 hours improving bioavailability and patient compliance. 

 S. Verma et al.,2011prepared gastroretentive drug delivery system of 
Stavudine. Guar gum, xanthan gum, and hydroxypropyl methylcellulose were


evaluated for gel-forming properties. Sodium bicarbonate was incorporated as 
a gas-generating agent. The proportion of sodium bicarbonate was varied to 
get the least possible lag time, also the polymer part varied to get the desired 
release. Tablets were prepared by the dry granulation (slugging). Tablets were 
evaluated for their physical characteristics, invitrobuoyancy & drug release 
studies using United State Pharmacopoeia (USP) 24 paddle type dissolution 
type apparatus using 0.1N HCl as a dissolution medium for 12 hours. The 
tablets exhibited controlled and prolonged drug release profiles while floating 
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over the dissolution medium. Non-Fickian diffusion was confirmed as the 
 
drug release mechanism from these tablets. 
 
3.3. PAST STUDIES ON FLOATING DRUG DELIVERY SYSTEMS OF GUM 
 
KONDAGOGU 
 
 Lakshmi Narasaiah.Vet al.,2010 developed an optimized gastric floating 
drug delivery system containing Metformin Hydrochloride using Gum


Kondagogu and investigate the effect of formulation and processing 
parameters. The effervescent granules were prepared by wet granulation 
technique using Gum Kondagogu as a controlled release natural polymer. 
Tablets were characterized for physical properties, floating characteristics 
(floating lag-time, floating time), swelling index, wetting time, drug content 

and evaluated for in vitro release characteristics for 10 hrs. The similarity 
factor, t50 and t90 were used as parameters for selection of the best 
formulation compared with commercial product.The drug release from all the 
formulations followed zero order kinetics and Korsmeyer-Peppas mechanism. 

 Lakshmi AP et al.,2011 prepared gastro retentive tablets of verapamil HCl by 
using different polymers like HPMC K4M, HPMC K100M and Gum


Kondagogu. Sodium bicarbonate is used as gas generating agent. The tablet 
exhibits controlled and prolonged drugrelease profile while floating over the 
dissolution medium. A combination of sodium bicarbonate (36mg) and citric 
acid (10mg) was found to achieve optimum in vitro buoyancy. Formulations 
of F1-F4 were prepared with HPMC K4M, and F5-F8 was prepared with 
HPMC K100M and F9-F11 was prepared with a combination of HPMC K4M 
and gum kondagogu.Out of the formulations F-1 to F-15, the best formulation 
(F9) was selected based on in vitro characterization. The drug release 
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mechanism from formulation F-9 confirmed to fallowed Non-Fickian 
diffusion . 
 
 Lakshmi P J et al.,2012 studied the influence of formulation variables on the 
release profile of diclofenac sodium from gum kondagogu matrix tablets.


Matrix tablets were prepared by wet granulation method. Physical properties 
and drug release studies were carried out for the prepared tablets. The physical 
properties indicated good handling properties of the prepared matrixtablets. 
Polynomial equations and response surface plots were generated for all 
dependent variables. This study indicates that both the factors have a 
significant effect on drug release profile. The dissolution studies indicate the 
release behavior of all the formulations was super case II transport mechanism 
with zero order kinetics. 

 Ravi Vet al.,2013 prepared floating tablets of diltiazem HCl using kondagogu 
gumas matrix forming carrier. The tablets were prepared by direct


compression technique using PVP K-30 as a binder, hydroxypropyl methyl 
cellulose (HPMCK4M) was employed in the formulation as a gel forming 
polymer and sodiumbicarbonate for development of CO2. The prepared matrix 
tablets were evaluated for properties such as hardness, thickness, friability, 
weight variation, floating lag time, compatibility using DSC and FTIR. In 
vitrodissolution was carried out for 12 hrs in 0.1N HCl buffer at 37±0.5 °C 
using USP basket type dissolutionapparatus. The drug release from prepared 
tablets was found to vary with varyingconcentration of the polymer, 
kondagogu gum. 
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3.4 PAST STUDIES ON FLOATING DRUG DELIVERY SYSTEMS OF GUM 
 
KARAYA. 
 
 Gangadharappa HVet al.,2010developed a single unit gastric floating drug 
delivery system of verapamil hydrochloride using karaya gum and


hydroxypropyl methylcellulose (HPMC) as polymers. The feasibility of 
karaya gum was used for the rate controlling of drug release in the 
development of floating drug delivery system, evaluating the prepared dosage 
forms for its sustained release, in vitro buoyancy, swelling index, drug 
content, and in vitro drug release. The floating matrix tablets were prepared by 
direct compression technique using a combination of hydroxyl propyl methyl 
cellulose (HPMC) and karaya gum as polymers and sodium bicarbonate as 
generating agent. The prepared floating tablets were evaluated for weight 
variation test, hardness, thickness, swelling index, in vitro floating 
capabilities, floating lag time, compatibility studies, and in vitro drug release. 
This swellable hydrophilic natural karaya gum was used to control the release 
of drug. The results showed that the optimized formulation F8 containing 
23.3% of karaya gum (70 mg) and 13.3% of HPMC (40 mg) had good floating 
capability, shorter Floating lag time and sustained drug release for the period 
of 8 hrs 

 Sreenivasa Reddy N et al.,2010developed Captoprilfloating matrix tablets by 
using Xanthan gum, Gum karaya, Gellan gum & Pullulan gum alongwith


HPMC K4M, PVP K-30, and Sodium bicarbonate . Sodiumbicarbonate was 
added as a gas generating agent, produced carbon dioxide in the gastric 
acidicenvironment which helped in maintaining the buoyancy. The prepared 
tablets were evaluated forphysical properties, content uniformity, hardness, 
friability, floating lag time and in vitro drug release.Among the studied 
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formulations, F9 was found to be suitable for gastric retention based on 
evaluationparameters, which was considered desirable for the drugs with 
absorption window in upper GIT. Thelinear regression analysis and model 
fitting showed that all these formulations followed Higuchi model,which had a 
higher value of correlation coefficient (r). Stability studies of all formulations 
werecarried out at elevated temperature and humidity conditions of 40±2 o 
C/75±5% RH and a controlsample was placed at ambient conditions for 12 
months. There was no significant change in buoyancyproperty and drug 
content, indicating that the formulations are stable 
 
 PK Lakshmiet al.,2013 prepared and evaluated the gastro retentive floating 
drug delivery system of Diltiazem hydrochloride by using natural polymers.


Thirteen tablet formulations were prepared by wet granulation usingdifferent 
concentrations of xanthan gum, karaya gum, guar gum, carrageenan as 
release-retarding polymers and sodium bicarbonate as a gas former. Swelling 
ability, floating behavior and drug release studies were conducted in 0.1N 
HCL (pH 1.2) at 37±0.5°C.The tablets showed acceptable physicochemical 
properties. Gastro retentive floating drug delivery system of Diltiazem 
hydrochloride using karaya gum, xanthan gum with drug to polymer ratio 1:5 
(F1) and 1: 3 (F3) respectively are final optimized formulations as these 
formulations produced better sustained drug release (99.96%, 99.27% release 
in 24 h) and having good floating properties. From the results of kinetic 
modeling of drug release, it can be concluded that the optimized formulations 
F1 follows zero order and F3 follows non-Fickian diffusion mechanism. 
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4. AIM AND OBJECTIVES 
 
 
 
Levofloxacin is a synthetic flouroquinoline antibacterial agent that inhibits 
bacterial DNA replication. It is L-isomer of Ofloxacin. It has a half life of 6hrsand the 
absorption of Levofloxacin is dose dependant, which increases with increase in dose. 
It is used in treating various infections caused by microorganisms like bacillus 
anthracis, Chlamydia infection, cystitis, epidydimitys, gonorrhea etc. The dose ranges 
from 250mg to 750mg.It is first choice drug used for treatment of Helicobacter pylori 
infections. Floating drug delivery system of Levofloxacin hemihydrates can localize 
the drug action within the stomach to treat gastric ulcers caused by Helicobacter 
pylori. 
 
 
In the present study, natural polymers such as gum kondagogu, gum 
karayaandxanthumgum are selected for the preparation of floating tablets of 
Levofloxacin hemihydrates. Sodium bicarbonate was used as gas generating agent. 
Tablets were prepared by wet granulation method using these polymers. 
 
 
The main objectives of this investigation are as follows: 
 
1. To isolate and extract natural polymers from their natural sources. 
 
2. To study the effect of sodium bicarbonate concentration and to optimize the 
concentration of gas generating agent. 
 
3. To conduct the compatibility studies of Levofloxacin hemihydrates with 
natural polymers by IR spectral studies. 
 
4. To formulate and evaluate Levofloxacin hemihydrate extended release 
floating tablets by Wet granulation method. 
 
5. To evaluate the formulated tablets according to the pharmacopeia standards. 
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6. To study the influence of natural polymers on release rate and to select the 
best release retarding polymer among them. 
 
7. To conduct comparative release studies among the natural polymers. 
 
8. To evaluate the mechanism and release kinetics of drug from the prepared 
tablets. 
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PLAN OF WORK 
 
 
 
The plan of work of the present studies are follows: 
 
 
 
 
To isolate and extract natural polymers from their natural sources.  
 
 
 
 
To conduct the compatibility studies of Levofloxacin hemihydrates with natural 
 
polymers by IR spectral studies.  
 
 
 
 
To formulate and evaluate Levofloxacin hemihydrate extended release floating 
 
tablets by Wet granulation method.  
 
 
 
 
To evaluate the formulated tablets according to the pharmacopeia standards.  
 
 
 
 
To study the influence of natural polymers on release rate and to select the best 
 
release retarding polymer among them.  
 
 
 
 
To conduct comparative release studies among the natural polymers.  
 
 
 
 
To evaluate the mechanism and release kinetics of drug from the prepared tablets. 
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5. EXPERIMENTAL INVESTIGATION 
 
5.1 Materials 
 
 
Table 5.1: Materials used in the present research work 
 
 
S.no Name of the product Name of the supplier 
   
1. Gum karaya 
Yarrow Chem. Products, 
Mumbai.   
   
2. Gum kondagogu 
Yarrow Chem. Products, 
Mumbai.   
   
3. HPMC K100M Hetero labs, Hyderabad 
   
4. Hydrochloric acid 
Qualigens fine chemicals, 
Mumbai.   
   
5. Isopropyl alcohol 
Qualigens fine chemicals, 
Mumbai.   
   
6. Levofloxacin hemihydrate Hetero labs, Hyderabad. 
   
7. Magnesium stearate SD fine chemicals, Mumbai. 
   
8. PVP K 30 
Qualigens fine chemicals, 
Mumbai.   
   
9. Sodium bicarbonate 
Qualigens fine chemicals, 
Mumbai.   
   
10 Talc SD fine chemicals, Mumbai. 
   
11 Xanthum gum Yucca enterprises, Mumbai. 
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5.2Instrumentation 
 
Table 5.2: Instruments used in the present work 
 
 
S. No. Name of the Instrument Model And Manufacturer/Supplier 
   
1. Centrifuge 
Cooling centrifuge C-24. Remi motors, 
Hyderabad.   
   
2. Electronic balance Shimadzu, A×200, Japan 
   
3. Glassware Borosil 
   
4. Hot air oven Thermolab, Mumbai. 
   
5. 
Rotary tablet compression 
Cadmach, Ahemadabad. 
machine   
   
6 
Tablet dissolution test Electrolab TDT 08L, dissolution tester, 
apparatus U.S.P.  
   
7 Tapped density apparatus Campbell electronics, Mumbai. 
   
8 
U.V/Visible ELICO SL 159, shimadzu UV spec 
spectrophotometer 1700.  
   
9 Viscometer 
Brookfield viscomerter, DV III Ultra, 
Brookfield inc, Brookfield, U.S.A.   
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5.3 M ethods 
 
5.3.1. Analytical methods of Levofloxacin hemihydrate. 
 
The following analytical methods are reported for the estimation of 
Levofloxacin hemihydrate. 
 
 UV Spectroscopy.

 Visible Spectroscopy.

 Gas Liquid Chromatography.

 High Pressure Liquid Chromatography.

 Thin Layer Chromatography.

 Paper Chromatography.

 Column Chromatography.

 Polarography.

 Titrimetry.
 
In this investigation, UV method is used for the estimation of Levofloxacin 
hemihydrate. 
 
 
5.3.2 Construction of calibration curve for Levofloxacin 
hemihydrate. 
 
The calibration curve was constructed with 0.1N HCl. Accurately weighed 
100 mg of Levofloxacin hemihydrate was transferred into 100 ml volumetric flask 
and dissolved in 0.1N HCl. Then volume was made up to the mark with 0.1N HCl to 
give a stock solution1 mg/ml. Further dilutions were made with 0.1N HCl to obtain 2 
to 10 µg/ml concentrations of Levofloxacin hemihydrate and the absorbance was 
measured at 293 nm. 
 
 
5.4 Viscosities of 1%w/v dispersions ofkaraya, gum kondagogu, 
xanthan gumand HPMC K 100 M IN 0.1N HCL. 
 
Viscosities of 1%w/v dispersion of gum karaya,gum kondagogu, 
 
xanthan gum and HPMC K 100 M in 0.1N HCl were measured by using Brookfield 
 
viscometer. 
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5.5Infra Red Spectral analysis 
 
IR Spectral analysis was used to study the interactions between the drug, 
polymer and the excipients. The drug and excipients must be compatible with one 
another to produce a product stable, efficacious and safe. 
 
5.6 Process optimization 
 
To study the influence of process variables such as concentration of sodium 
bicarbonateand drug release, floating tablets were prepared by employing effervescent 
technology. Different concentration of NaHCO3 were used ( 15%, 20% and 25%) for 
process optimization. 
 
5.7. Preparation of Levofloxacin hemihydrate floating tablets 
 
Floating tablets of Levofloxacin hemihydrate were prepared by using different 
drug: polymer (Levofloxacin hemihydrates+HPMC K100M+Natural polymer) ratios. 
The tablets were formulated by employing wet granulation method using PVP K 30 as 
binder and isopropyl alcohol as granulating fluid. All the formulations contain250 mg 
of Levofloxacin hemihydrate, sodium bicarbonate as gas generating agent, 
magnesiumstearate as lubricant and talc added as glidant. The details of composition 
of each formulation are given in Tables 5.3-5.7. 
 
5.3: Composition of Levofloxacin hemihydrate floating tablets formulated with 
different concentrations of gum karaya 
Ingredients F1(mg) F2(mg) F3(mg) F4(mg) F5(mg) 
      
Levofloxacin hemihydrate 250 250 250 250 250 
      
HPMC K 100 M 120 90 60 30 0 
      
Gum karaya 0 30 60 90 120 
      
Sodium bicarbonate 100 100 100 100 100 
      
PVP K 30 5 5 5 5 5 
 
      
Magnesium stearate 12 12 12 12 12 
      
Talc (2%) 13 13 13 13 13 
      
Total weight 500 500 500 500 500 
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Table 5.4: Composition of Levofloxacin hemihydrate floating tablets 
formulated with different concentrations of xanthan gum. 
 
 
 
 
Ingredients F6 (mg) F7 (mg) F8(mg) F9 (mg) 
     
Levofloxacin hemihydrates 250 250 250 250 
 
     
HPMC K100M 90 60 30 0 
     
Xanthan gum 30 60 90 120 
     
Sodium bicarbonate 110 110 115 115 
     
PVP K 30 5 5 5 5 
     
Magnesium stearate 7.5 7.5 5 5 
     
Talc 7.5 7.5 5 5 
     
Total weight 500 500 500 500 
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Table 5.5: Composition of Levofloxacin hemihydrate floating tablets 
formulated with different concentrations of gum kondagogu. 
 
 
Ingredients F10 (mg) F11 (mg) F12 (mg) F13 (mg) 
     
Levofloxacin hemihydrate 250 250 250 250 
     
HPMC K 100 M 90 60 30 0 
     
Gum Kondagogu 30 60 90 120 
     
Sodium bicarbonate 100 110 110 110 
     
PVP K 30 5 5 5 5 
     
Magnesium stearate 12 7.5 7.5 7.5 
     
Talc 13 7.5 7.5 7.5 
     
Total 500 500 500 500 
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5.10 Evaluation Parameters 
 
5.10.1 Flow properties of granules.
3 
 
a) Bulk Density (Db): It is the ratio of total mass of granules to the bulk volume 
of granules. It was measured bypouring the granules (passed through standard 
sieve # 20) into a measuring cylinder and initial weight will be noted. This 
initial volume is called bulk volume. From this the bulkdensity was calculated 
according to the formula mentioned below. It is expressed in g/ml and isgiven 
by 
 
Bulk Density (g/ml) = Mass of the powder/Bulk Volume 
 
 
b) Tapped Density (Dt): It is the ratio of total mass of the granules to the tapped 
volume of the granules. Volume was measured by tapping the granules for 750 
times and the tapped volume will be noted, if thedifference between these two 
volumes is less than 2%. If it is more than 2%, tapping wascontinued for 1250 
times and tapped volume was noted. Tapping was continued until 
thedifference between successive volumes is less than 2 % (in a bulk density 
apparatus). It isexpressed in g/ml and is given by 
 
Tapped density (g/ml) = Mass of the powder/Tapped volume 
 
 
c) Angle of Repose (ө): The friction forces in greanules can be measured by the 
angle of repose (ө). It is an indicative of the flow properties of the powder. It is 
defined as maximum angle possible between the surface of the pile of granules 
and the horizontal plane. The granules were allowed to flow through the 
funnel fixed to a stand at definite height (h). The angle of repose was 
calculated by measuring the height and radius of the heap of granules formed. 
 
= tan-1(h / r) 
 
Where, is the angle of repose. 
 
h is the height in cms 
 
r is the radius in cms 
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d) Carr’s index (or) % compressibility: It indicates granule flow properties. It is 
expressed in percentage and is given by 
 
Carr’s Index (%) = [(Tapped density – Bulk Density) / Tapped Density] × 
 
100 
 
 
e) Hausner ratio: Hausner ratio is an indirect index of ease of granules flow. It 
is calculated by the followingformula. 
 
Hausner’s Ratio = Tapped density / Bulk Density 
 
 
5.10.2 Evaluation of tablets 
 
a) Hardness
4
: The hardness of the tablet was measured by Monsanto hardness 
tester. The lower plunger was placed in contact with the tablet and a zero 
reading was taken. The plunger was then forced against a spring by tuning a 
threaded bolt untilthe tablet fractured. As the spring was compressed a pointer 
rides along a gauge in the barrel to indicate the force. The hardness was 
measured in terms of kg/cm
2
. 
 
b) Drug content
4
:20 tablets were weighed and powderedthe powder weight 
equivalent to 100mg of Levofloxacin trihydrate was dissolved in 100ml of 
0.1N HCl and filtered. 5ml of this was diluted to 50ml with water and drug 
content was estimated using UV-VISIBLE spectrophotometer at 293nm. 
 
 
c) Weight variation
4
:Formulated tablets were tested for weight uniformity, 20 
tablets were weighed collectively and individually. From the collective 
weight, average weight was calculated. The percent weight variation was 
calculated by using the following formula. 
 
% Weight Variation = Average Weight - Individual Weight 
X100 Average Weight 
 
d) Friability
4
: The Roche friability test apparatus was used to determine the 
friability of the tablets. Twenty pre-weighed tablets were placed in the 
apparatus and operated for 100 revolutions and then the tablets were 
reweighed. The percentage friability was calculated according to the following 
formula. 
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Friability = Initial Weight - Final Weight X 100  
Initial Weight 
 
e) Swelling Index
5
: Formulated tablets were weighed individually (W0) and 
placed separately in Petri dish containing 50 ml of 0.1 N HCl. The Petri dishes 
were placed in an incubator maintained at 37±0.5
o
C. The tablets were 
removed from thepetri dish, at predefined intervals of time and reweighed 
(Wt), and the % swelling index was calculated using the following formula: 
 
% WU = (Wt-Wo/Wo) × 100 
 
Where: 
 
WU – Water uptake 
 
Wt – Weight of tablet at time t 
 
Wo – Weight of tablet before immersion 
 
 
f) In vitro buoyancy study
6
: This test is characterized by floating lag time and 
total floating time. The test was performed using USP-Type II paddle 
apparatus using 900 ml of 0.1N HCl at paddle rotation of 100 rpm at 37 ± 0.5
0
 
C. The time required for tablet to rise to surface of dissolution medium and 
duration of time the tablet constantly float on dissolution medium was noted 
as floating lag time and total floating time. 
 
 
g) In vitro dissolution test
7
:The release of Levofloxacin hemihydratefrom the 
tablet was studied using USP-Type II paddle apparatus. Drug release profile 
was carried out in 900 ml of 0.1N HCl maintained at 37 ± 0.5°C temperatures 
at 100 rpm. 5 ml of samples were withdrawn at regular time intervals. The 
samples was replaced by its equivalent volume of dissolution medium and was 
filtered through 0.45 µm Whatman filter paper and analyzed at 293 nm by UV 
spectrophotometer. 
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6. EXPERIMENTAL RESULTS 
 
6.1 Construction of calibration cure for Levofloxacin hemihydrate in 0.1N HCl 
 
 Concentration Absorbance 
S.NO (µg/ml) 
   
( X ± s d) 
1. 0 0 
   
2. 2 0.194±0.005 
   
3. 4 0.385±0.008 
   
4. 6 0.580±0.003 
   
5. 8 0.762±0.002 
   
6. 10 0.940±0.007 
     
 
 
 
 
Fig 6.1: Standard Calibration Curve of Levofloxacin hemihydrate in 0.1 N HCl  
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Table 6.2.Viscosities of 1%w/v dispersions ofXanthum gum, Gum 
kondagoguand Gum karaya. 
 
 
S.NO POLYMER  
  VISCOSITY(Cps) 
   
1 Xanthum gum 2171.54 
   
2 Gum kondagogu 450.54 
   
3 Gum karaya 385.95 
   
 
 
 
 
 
 
 
 
Table 6.3.Viscosities of 1%w/v dispersions of HPMC K 100 M .  
 
 
 
 
S.NO POLYMER 
VISCOSITY(Cps) 
 
1 HPMC K 100M 1205.74 
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Table 6.4: Micromeritic properties of Levofloxacin hemihydrate granules 
formulated with different concentrations of gum karaya 
 
Formulatio Angle of Bulk Tapped Compressibilit Haussners 
n code repose density density y index ratio 
      
F1 26.94±0.02 0.276±0.01 0.314±0.01 12.10±0.024 1.137±0.01 
 1 4 3  2 
      
F2 25.6±0.031 0.350±0.01 0.408±0.01 14.21±0.022 1.161±0.01 
  2 1  4 
      
F3 25.42±0.05 0.320±0.02 0.370±0.00 11.89±0.009 1.134±0.01 
 2 0 9  7 
      
F4 26.85±0.02 0.319±0.00 0.362±0.02 11.87±0.017 1.130±0.02 
 4 5 1  4 
      
F5 27.01±0.03 0.351±0.00 0.393±0.01 10.68±0.014 1.119±0.01 
 5 9 9  4 
      
 
 
 
 
 
 
Table 6.5: Physical properties of Levofloxacin hemihydrates floating tablets 
formulated with different concentrations of gum karaya. 
 
  
Weight 
   Total 
 
Hardness Friability Drug Floating floating 
Formulation variation (kg/cm2) (%) content (%) Lag time time 
  (mg)    (hrs) 
      
       
F1 4.7±0.021 501.32±0.24 0.40±0.010 100.14±0.13 1.25 min >14 
       
F2 4.5±0.025 500.65±0.28 0.34±0.018 99.78±0.15 2.12 min >14 
       
F3 4.8±0.032 499.83±0.39 0.45±0.024 99.56±0.11 3.35 min 13 
       
F4 4.6±0.038 500.12±0.45 0.61±0.036 100.15±0.38 4.40 min 11 
       
F5 5.1±0.042 499.76±0.54 0.67±0.048 100.78±0.87 7.30 min 10 
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Table 6.6: In vitro release data of Levofloxacin hemihydrate floating tablets formulated 
with different concentrations of gum karaya 
 
 
  % Levofloxacin Released (X ± s.d.)  
Time (hrs) 
     
F1 F2 F3 
 
F5  
F4      
0 0.00 0.00 0.00 0.00 0.00 
      
0.5 5.14±0.12 5.79±0.21 18.92±0.12 20.21±0.15 20.45±0.14 
      
1 7.68±0.09 8.91±0.19 20.70±0.14 23.34±0.11 23.57±0.09 
      
1.5 9.75±0.11 11.50±0.11 22.84±0.18 25.38±0.14 25.58±0.15 
      
2 12.43±0.06 15.67±0.09 24.57±0.09 28.92±0.09 29.15±0.07 
      
2.5 15.35±0.08 19.76±0.16 27.83±0.05 31.60±0.05 31.83±0.16 
      
3 18.62±0.15 22.88±0.11 31.35±0.13 33.76±0.07 33.99±0.14 
      
3.5 21.66±0.17 25.95±0.14 35.75±0.17 36.19±0.16 36.43±0.17 
      
4 23.42±0.15 28.88±0.13 38.24±0.11 44.48±0.09 46.78±0.07 
      
4.5 26.00±0.06 30.98±0.18 45.36±0.18 47.78±0.12 50.09±0.09 
      
5 29.27±0.03 34.55±0.14 50.56±0.14 49.94±0.08 52.65±0.14 
      
5.5 34.39±0.07 38.25±0.16 54.27±0.21 55.56±0.14 57.90±0.13 
      
6 35.57±0.12 39.37±0.06 56.09±0.15 60.82±0.19 63.17±0.11 
      
6.5 39.00±0.15 50.27±0.05 61.74±0.17 68.78±0.16 71.14±0.09 
      
7 48.34±0.19 55.89±0.19 65.50±0.13 71.06±0.09 73.43±0.05 
      
7.5 52.03±0.09 59.24±0.15 71.20±0.18 76.02±0.07 78.41±0.10 
      
8 56.13±0.06 64.14±0.18 77.68±0.16 82.91±0.16 85.31±0.07 
      
8.5 58.72±0.18 67.15±0.14 80.39±0.18 85.64±0.14 88.44±0.16 
      
9 62.09±0.14 70.18±0.12 82.72±0.14 87.62±0.16 91.20±0.17 
      
9.5 65.47±0.26 73.99±0.11 85.45±0.16 89.23±0.06 93.59±0.06 
      
10 67.35±0.18 76.67±0.08 87.04±05 91.60±0.09 -- 
      
10.5 70.37±0.20 78.99±0.06 89.03±0.19 93.99±0.14 -- 
      
11 73.03±0.11 81.69±0.20 90.63±0.15 95.63±0.09 -- 
      
11.5 75.71±0.09 85.17±0.18 92.63±0.14 -- -- 
      
12 78.78±0.13 87.15±0.14 94.26±0.18 -- -- 
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Table 6.7: In vitrodrug release kinetic data of Levofloxacin hemihydrate floating 
tablets formulated with different concentrations of gum karaya. 
 
 
 Correlation CoefficieSnt Value Release    
     
Rate Exponenti 
T50 T90 
     
Formulatio Zero First 
  
Constan al 
Matri Peppa (hr (hr 
n Orde Orde t Coefficient 
x s ) )  
r r (mg/hr)k (n)      
     0    
F1 
0.995 0.962 
0.9065 0.9907 16.5772 0.9411 7.5 
13. 
8 0 6       
F2 
0.996 0.953 
0.9179 0.9939 18.8651 0.9202 6.6 
11. 
1 1 9       
F3 
0.970 0.961 
0.9628 0.9674 22.2475 0.6221 5.6 
10. 
6 1 1       
F4 
0.968 0.945 
0.9621 0.9653 24.3660 0.5957 5.1 9.2 
8 2        
F5 
0.975 0.933 
0.9549 0.9584 26.4037 0.5921 4.7 8.5 
2 9        
 
 
 
 
 
Figure 6.2: Comparative in vitrodrug release profile of Levofloxacin hemihydrate 
floating tablets formulatedwith different concentrations of gum karaya.  
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Figure 6.3: Comparative Zero order plots of Levofloxacin hemihydrate 
floatingtablets formulated with different concentrations of gum karaya  
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Figure 6.4: Comparative Peppas plots of Levofloxacin hemihydrate 
floatingtablets formulated with different concentrations ofgum karaya  
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Table 6.8:Swelling index values of Levofloxacin hemihydrate 
tablets formulated withdifferent concentrations of gum karaya 
 
 
  Swelling index  
Formulation code 
   
 Time in hours  
    
 after 1 hour after 2 hours after 8hours 
    
F1 63.22 79.59 118.00 
    
F2 81.63 87.62 120.21 
    
F3 82.00 98.00 132.42 
    
F4 86.50 100.39 148.97 
    
F5 94.68 104.77 157.62 
    
 
 
 
 
 
 
Figure 6.5. Comparative swelling index plot of Levofloxacin hemihydrate floating 
tablets formulated with different concentrations of gum karaya  
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Table 6.9: Micromeritic properties of Levofloxacin hemihydrate granules 
formulated with different concentrations of xanthum gum. 
 
Formulatio Angle of Bulk Tapped Compressibili Haussners 
n code repose density density ty index ratio 
      
F6 25.76±0.05 0.255±0.02 0.291±0.00 12.37±0.024 1.142±0.01 
  5 5  4 
      
F7 26.40.0±0.0 0.271±0.02 0.316±0.01 14.240±0.019 1.166±0.01 
 7 1 1  9 
      
F8 27.32±0.09 0.314±0.01 0.366±0.01 14.207±0.027 1.165±0.01 
  8 9  1 
      
F9 26.54±0.13 0.353±0.02 0.400±0.01 11.750±0.017 1.133±0.02 
  7 4  7 
      
 
 
 
 
 
 
Table 6.10: Physical properties of Levofloxacin hemihydrate floating tablets 
formulated with different concentrations of xanthum gum. 
 
 
 
  
Weight 
   Total 
 
Hardness Friability Drug Floating floating 
Formulation variation (kg/cm2) (%) content (%) Lag time time 
  (mg)    (hrs) 
      
       
F6 4.6±0.048 501.36±0.54 0.39±0.025 101.52±0.23 1.98 min >15 
       
F7 4.4±0.032 501.66±0.49 0.35±0.019 99.87±0.41 3.25 min >18 
       
F8 4.7±0.029 499.91±0.39 0.42±0.026 101.93±0.16 5.02 min >22 
F9 5.2±0.054 500.08±0.51 0.40±0.032 100.23±0.46 6min >22 
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Table 6.11: In vitro release data of Levofloxacin hemihydrate floating tablets 
formulated with different concentrations of xanthum gum. 
 
Time(hrs) 
 % Levofloxacin Released (X±s.d.)  
     
F1 F6 F7 F8 F9  
      
0 0.00 0.00 0.00 0.00 0.00 
      
0.5 5.14±0.12 6.36±0.09 5.25±0.08 3.99±0.15 4.64±0.06 
      
1 7.68±0.09 8.26±0.12 7.30±0.17 6.07±0.04 6.35±0.04 
      
1.5 9.75±0.11 11.48±0.15 8.87±0.16 8.25±0.16 8.02±0.11 
      
2 12.43±0.06 13.79±0.08 10.43±0.12 9.90±0.09 9.71±0.19 
      
2.5 15.35±0.08 15.44±0.14 13.1±0.06 14.00±0.20 11.11±0.20 
      
3 18.62±0.15 16.89±0.17 15.77±0.04 16.21±0.16 13.19±0.16 
      
3.5 21.66±0.17 19.28±0.21 18.18±0.09 19.01±0.11 14.59±0.18 
      
4 23.42±0.15 20.91±0.16 20.27±0.16 21.40±0.14 16.39±0.14 
      
4.5 26.00±0.06 22.97±0.07 24.23±0.11 23.77±0.07 18.31±0.09 
      
5 29.27±0.03 24.47±0.09 27.08±0.19 25.66±0.18 23.22±0.17 
      
5.5 34.39±0.07 27.32±0.14 27.41±0.15 28.51±0.16 26.21±0.13 
      
6 35.57±0.12 29.60±0.16 30.20±0.14 31.41±0.14 29.21±0.20 
      
6.5 39.00±0.15 34.56±0.18 33.49±0.03 35.02±0.05 32.23±0.09 
      
7 48.34±0.19 37.92±0.21 35.610±0.18 37.11±0.09 34.24±0.05 
      
7.5 52.03±0.09 54.12±0.06 38.97±0.21 43.76±0.07 38.32±0.17 
      
8 56.13±0.06 59.37±0.11 56.17±0.16 47.82±0.13 39.97±0.13 
      
8.5 58.72±0.18 60.45±0.19 57.62±0.07 49.98±0.18 38.66±0.11 
      
9 62.09±0.14 62.69±0.09 59.84±0.09 52.54±0.11 40.77±0.04 
      
9.5 65.47±0.26 64.17±0.07 61.30±0.18 55.11±0.07 42.52±0.08 
      
10 67.35±0.18 66.42±0.18 62.39±0.11 56.12±0.04 43.89±0.16 
      
10.5 70.37±0.20 69.06±0.09 65.39±0.04 59.13±0.12 47.17±0.07 
      
11 73.03±0.11 71.71±0.13 67.65±0.09 62.88±0.19 50.47±0.14 
      
11.5 75.71±0.09 73.62±0.06 70.29±0.05 66.26±0.16 55.32±0.19 
      
12 78.78±0.13 75.53±0.18 73.33±0.15 69.28±0.09 60.57±0.20 
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Table 6.12: Comparative in vitrodrug release profile of Levofloxacin hemihydrate 
floating tablets formulatedwith different concentrations of xanthum gum. 
 
 
 Correlation Coefficient Value Release    
     
Rate Exponenti 
  
       
Formulatio Zero First 
Matri Peppa 
Constan al 
T50 T90 
n Orde Orde t Coefficient 
x s 
  
 
r r (mg/hr)k (n) 
  
     
     0    
         
F1 
0.995 0.962 
0.9065 0.9907 16.5772 0.9411 7.5 
13. 
8 0 6       
         
F6 
0.980 0.947 
0.8822 0.9689 16.0000 0.8777 7.8 
14. 
6 6 1       
         
F7 
0.984 0.949 
0.8835 0.9790 15.1187 0.9330 8.3 
14. 
9 9 9       
         
F8 
0.997 0.971 
0.9081 0.9943 14.1717 0.9607 8.8 
15. 
3 6 9       
         
F9 
0.993 0.976 
0.9135 0.9845 11.7362 0.8705 
10. 19. 
6 4 7 2      
         
 
Figure 6.6: Comparative in vitrodrug release profile of Levofloxacin hemihydrate 
floating tablets formulatedwith different concentrations of xanthum gum  
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Figure 6.7: Comparative Zero order plots of Levofloxacin hemihydrate 
floatingtablets formulated with different concentrations of xanthum gum  
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Figure 6.8: Comparative Peppas plots of Levofloxacin hemihydrate 
floatingtablets formulated with different concentrations ofxanthum gum.  
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Table 6.13:Swelling index values of Levofloxacin hemihydrates tablets 
formulated with different concentrations of xanthum gum. 
 
 
  Swelling index  
Formulation code 
   
 Time in hours  
    
 after 1 hour after 2 hours after 8hours 
    
F6 52.69 76.64 145.00 
    
F7 53.53 89.89 154.00 
    
F8 58.53 96.10 168.50 
    
F9 65.33 105.41 171.34 
    
 
 
 
 
 
Figure 6.9:Comparative swelling index plot of Levofloxacin hemihydrate floating 
tablets formulated with xanthum gum.  
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Table 6.14: Micromeritic properties of Levofloxacin hemihydrate granules 
formulated with different concentrations of gum kondagogu. 
 
 
Formulation Angle of Bulk Tapped Compressibility Haussners 
code repose density density index ratio 
      
F10 29.89±0.241 0.268±0.011 0.307±0.025 12.70±0.019 1.145±0.019 
      
F11 28.41±0.250 0.271±0.021 0.313±0.017 13.41±0.011 1.154±0.014 
      
F12 29.33±0.214 0.280±0.017 0.320±0.031 12.50±0.024 1.142±0.025 
      
F13 30.81±0.233 0.281±0.015 0.319±0.019 12.70±0.016 1.146±0.017 
      
 
 
 
 
 
Table 6.15: Physical properties of Levofloxacin hemihydrate floating tablets 
formulated with different concentrations of gum kondagogu 
 
 
 
 
Hardness Weight Friability Drug 
Floating Total 
Formulation lag time 
floating 
(kg/cm
2
) variation(mg) (%) content(%) 
time      (min) 
F10 4.8±0.044 500.47±0.44 0.62±0.024 99.45±0.15 1.40 >14 
       
F11 4.7±0.027 501.39±0.94 0.37±0.012 101.89±0.16 2 13 
       
F12 4.2±0.082 499.54±0.55 0.37±0.101 99.58±0.17 2.15 13 
       
F13 4.5±0.023 500.34±0.60 0.39±0.124 101.45±0.13 3.15 11 
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Table 6.16: In vitro release data of Levofloxacin hemihydrate floating tablets 
formulated with different concentrations of gum kondagogu 
 
 
Time (hrs) 
 % Levofloxacin Released (X±s.d.)  
     
F1 F10 F11 F12 F13  
0 0.00 0.00 0.00 0.00 0.00 
      
0.5 5.14±0.12 8.42±0.05 15.79±0.09 16.25±0.15 18.05±0.17 
      
1 7.68±0.09 10.44±0.08 17.67±0.013 18.82±0.018 20.35±0.19 
      
1.5 9.75±0.11 12.84±0.10 19.87±0.12 21.02±0.17 22.30±0.20 
      
2 12.43±0.06 14.78±0.10 23.07±0.15 24.15±0.19 24.48±0.21 
      
2.5 15.35±0.08 17.95±0.08 26.40±0.12 27.53±0.15 28.21±0.021 
      
3 18.62±0.15 21.53±0.15 28.38±0.16 29.67±0.18 29.58±0.19 
      
3.5 21.66±0.17 23.93±0.12 30.25±0.15 31.09±0.17 32.80±0.20 
      
4 23.42±0.15 26.58±0.14 32.82±0.16 34.00±0.21 34.23±0.19 
      
4.5 26.00±0.06 28.33±0.13 34.83±0.16 38.77±0.19 37.13±0.21 
      
5 29.27±0.03 31.08±0.16 38.34±0.12 47.76±0.18 53.52±0.20 
      
5.5 34.39±0.07 33.84±0.12 42.17±0.14 53.36±0.016 56.86±0.12 
      
6 35.57±0.12 36.09±0.10 48.89±0.18 58.99±0.015 55.26±0.15 
      
6.5 39.00±0.15 38.08±0.08 55.6±0.19 62.37±0.09 59.75±0.18 
      
7 48.34±0.19 45.04±0.06 60.14±0.21 63.46±0.08 63.13±0.21 
      
7.5 52.03±0.09 55.97±0.05 64.28±0.14 66.47±0.05 66.14±0.17 
      
8 56.13±0.06 63.14±0.12 66.53±0.17 72.17±0.0.17 77.56±0.19 
      
8.5 58.72±0.18 66.53±0.13 68.79±0.20 74.46±0.13 80.26±0.16 
      
9 62.09±0.14 68.41±0.17 70.68±0.19 77.53±0.14 82.60±0.13 
      
9.5 65.47±0.26 70.31±0.17 72.96±0.12 80.23±0.10 86.09±0.10 
      
10 67.35±0.18 72.97±0.21 74.87±0.15 82.56±0.09 88.07±0.15 
      
10.5 70.37±0.20 76.03±0.20 77.56±0.10 84.90±0.06 90.44±0.19 
      
11 73.03±0.11 78.34±0.16 81.01±0.16 86.49±0.12 93.20±0.21 
      
11.5 75.71±0.09 80.27±0.18 83.72±0.14 88.46±0.15 -- 
      
12 78.78±0.13 82.98±0.14 85.69±0.16 91.21±0.20 -- 
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Table 6.17: Comparative in vitrodrug release profile of 
Levofloxacin hemihydrate floating tablets formulatedwith 
different concentrations of gum kondagogu 
 
 
 
 
 Correlation Coefficient Value Release    
     
Rate Exponenti 
  
       
Formulatio Zero First 
Matri Peppa 
Constan al T5 
T90 
n Orde Orde t Coefficient 
 
x s 
0  
 
r r (mg/hr)k (n) 
  
     
     0    
         
F1 
0.995 0.962 
0.9065 0.9907 16.5772 0.9411 7.5 
13. 
8 0 6       
         
F10 
0.989 0.949 
0.9038 0.9742 17.7442 0.8250 7 
12. 
2 0 7       
         
F11 
0.976 0.975 
0.9552 0.9671 19.4295 0.6271 6.4 
11. 
1 6 6       
         
F12 
0.973 0.972 
0.9602 0.9708 21.1625 0.6449 5.9 
10. 
3 5 6       
         
F13 
0.978 0.941 
0.9451 0.9543 22.7780 0.6307 5.5 9.9 
8 6        
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Figure 6.10: Comparative in vitrodrug release profile of Levofloxacin 
hemihydrate floating tablets formulatedwith different concentrations of 
gum kondagogu  
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Figure 6.11: Comparative Zero order plot of levofloxacin hemihydrate 
floatingtablets formulated with different concentrations of gum kondagogu  
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Figure 6.12: Comparative Peppas plots of Levofloxacin hemihydrate floatingtablets 
formulated with different concentrations ofgum kondagogu  
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Table 6.18:Swelling index values of Levofloxacin hemihydrates tablets 
formulated with different concentrations of gum kondagogu 
 
 
 
Formulation code  Swelling index  
    
  Time in hours  
    
 after 1 hour after 2 hours after 8hours 
    
F10 66.99 83.89 148.50 
    
F11 68.34 86.49 157.05 
    
F12 57.06 80.91 155.46 
    
F13 56.31 79.35 137.42 
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Figure 6.13: Comparative swelling index plot of Levofloxacin hemihydrate 
floating tablets formulated with gum kondagogu  
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Figure: 6.14. IR spectrum of Levofloxacin hemihydratre. 
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Figure: 6.15. IR spectrum of Levofloxacin+ gum karaya.  
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Figure: 6.20. IR spectrum of Levofloxacin + xanthum gum  
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 Figure: 6.21. IR spectrum of Levofloxacin+ gumkondagogu  
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7. RESULTS AND 
DISCUSSION 7.1 Calibration curve 
 
The absorbance values and standard plots were shown in table 6.1 and fig 6.1. 
From these results it was found that there exists a good correlation between 
concentration and absorbance values. 
 
7.2 Process optimization 
 
The process optimization studies were carried out to determine the 
concentration of NaHCO3 based on lag time and drug release. The gas generating 
components such as carbonates and composition. Increasing the concentration of 
sodium bicarbonate decreases the floating lag time because of faster and higher 
carbon dioxide generation. 
 
In the present investigation 20-23%w/w NaHCO3 was selected as optimized 
concentration, as it showed less lag time when compared with other concentrations of 
NaHCO3. 
 
7.3 Viscosity of polymers 
 
Viscosities of 1%w/v HPMC K 100 M, xanthum gum, gumkondagogu and 
gum karayawere measured in 0.1N HCl.Viscosity values were in order of xanthum 
gum >HPMC K 100 M>gumkondagogu>gum karaya.Viscosity values were showed 
in table 6.2 and table 6.3. 
 
7.4Studies on Levofloxacin hemihydrates floating tablets formulated with 
different concentrations of gum karaya. 
 
Floating tablets (F1-F5) of Levofloxacinhemihydrate were prepared by 
varying the concentration of HPMC K 100 M and gum karaya. The composition of 
the formulations is shown in table 5.3. 
 
The formulated granules were evaluated for various flow properties.The bulk 
density for all theformulations ranged from 0.276 to 0.351. The angle of repose for all 
the formulations was found to be in the range of 25
0
42
1
-27
0
01
1. The Carr’s index for 
all the formulations ranged from 10.68 – 12.01%. The value of bulk density indicates 
good packing characters. The value of angle of repose (25
0
-30
0
) for all the 
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formulations indicates good flow property. The value of Carr’s index (10-16%) 
indicates free flowing material. The values of Hausner’s ratio were found to be 
between 1.119-1.161. The powder blend with Hauser’s ratio of 1.25 has good flow 
properties. So the values indicate that the granules had acceptable flow properties. 
The flow properties were shown in table 6.4 
 
Floating matrix tablets were evaluated for hardness and friability. The 
hardness was found to be in between 4.5 – 5.1 kg. The tablets satisfied friability 
requirement, as the % friability values were less than 1%.The drug content estimations 
showed values in the range of 99.56 to 100.78%, which reflects good uniformity in 
drug content among different formulations. All the tablets passed weight variation test 
as the % weight variation was within the Pharmacopoeia limits of ±5% of the weight. 
All the formulations showed values within the prescribed limits for tests like hardness, 
friability and weight variation which indicate that the prepared tablets are of standard 
quality. 
 
 
All the tablets were formulated using sodium bicarbonate as effervescent 
agent. It was observed that the carbon dioxide generated from sodium bicarbonate in 
presence of dissolution medium(0.1N HCL) was trapped in the polymer gel matrix 
formed by the hydration of polymers(HPMC K100M orgum karaya) which decreases 
the density(<1) and makes the tablet buoyant. The tablets formulated with gum 
karaya(F1-F5) contained the same amount of Sodium bicarbonate as effervescent 
agent but showed a increased in floating lag time with increase in concentration of 
natural polymer. The buoyancy studies results showed that the formulations 
containing higher concentration of HPMC K 100M, showed good floating lag time 
(FLT) and total floating time (TFT) when compared to formulations containing higher 
concentrations of natural polymer. The results of various physical properties 
andinvitro buoyancy studies were tabulated in table 6.5. 
 
 
In vitro dissolution studies of all the formulations of floating matrix tablets 
were carried out in 0.1N HCl. The study was performed for 12 hrs and the cumulative 
drug release was calculated. All the formulations remained floating and intact 
throughout the dissolution studies. The formulations(F2-F4) containing gum karayain 
combination with HPMC K100M showed increase in drug release with increase in 
concentration of gum karayawhen compared formulation containing only HPMC 
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K100M. The drug release from formulation F5 containing only gum karayashowed a 
maximum drug release at end of 10 hours. Drug release from the formulation 
containing HPMC K100M was lesser owing to its high viscosity and also due to less 
permeability of water, as the drug release rate is dependent on the viscosity grade and 
the concentration of the polymers used. The dissolution profile for the formulations is 
tabulated in table 6.6 and shown in figure 6.2. 
 
 
To ascertain the mechanism of drug release, the dissolution data was analyzed 
by zero order, first order, and Higuchi and Peppas equations. The correlation 
coefficient values (r) revealed that the dissolution profiles follows Zero order kinetics 
and the mechanism of drug release was governed by Peppas model. The n values are 
found to be more than 0.5 (n>0.5) indicted that the drug release was predominantly 
controlled by non fickian diffusion. . The in-vitro drug release kinetic data was shown 
in table 6.7 and figures 6.3 and 6.4. 
 
The swelling index studies showed a gradual increase with increase in 
concentration of gum karayawhich indicates the natural tendency of it to swell 5-10 
times of its original value. The swelling index values are shown in table 6.8 and figure 
6.5. 
 
7.5 Studies on Levofloxacin hemihydrate floating tablets formulated 
with different concentrations of xanthum gum. 
 
To study the influence of xanthum gum concentration on drug release, 
formulations (F6-F9) were prepared using different concentrations of xanthum gum 
with HPMC K100M by wet granulation method. The composition of formulations F6-
F9 is shown in table 5.4 .The formulated granules were subjected to various 
micromeritic properties and the values were shown in table 6.9. All the formulations 
exhibited the desirable flow properties. 
 
The formulated tablets were subjected to various quality control tests like 
hardness, friability, weight variation and drug content. All the tablets complied with 
the pharmacopoeia standards. In the case of tablets formulated with guar gum (F6-F9) 
amount of sodium bicarbonate required for floating increased with increase in 
xanthum gumconcentration which indicated that the molecular weight distribution or 
viscosity of the gel forming polymers influenced the in vitro buoyancy. The various 
physical properties are shown in table 6.10. 
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The formulations(F6-F9) containing xanthum gum in combination with HPMC 
K100M showed decrease in drug release with increase in concentration of xanthum 
gum when compared formulation containing only HPMC K100M(F1). The drug 
release from the formulations (F6-F9) showed very slow release as compared to other 
formulations. The in vitro release data for formulations (F6-F9) was presented in table 
6.11 and fig 6.6. The release rate followed zero-order release kinetics (fig 6.7) and the 
data was fitted in the Peppas plots (fig 6.8).The exponential coefficient from the 
Peppas plots was found to be in between 0.75 to 0.88, indicating non fickian 
mechanism of drug release. Drug release kinetic data was presented in table 6.12. The 
release rate of Levofloxacin hemihydrate was found to be retarded by xanthum 
gumwith an increase in its concentration. 
 
The swelling indexof tablets formulated with xanthum gum(F6-F9) was found 
to be higher than that of other formulations which can be attributed tohigh viscosity 
and high water retention property of both HPMC K100M and xanthum gum. The 
values of swelling index are tabulated in table 6.13 and shown in figure 6.9. 
 
7.6 Studies on Levofloxacin hemihydrate floating tablets formulated 
with different concentrations of gumkondagogu. 
 
To study the influence of gum kondagoguconcentration on drug release, 
formulations (F10-F1) were prepared using different concentrations of gum 
kondagoguand HPMC K 100 M by wet granulation method as given in table 5.5 
 
The granules were subjected to various micromeritic properties and the values 
were shown in table 5.14. All the formulations exhibited the desirable flow properties. 
The formulated tablets were subjected to various quality control tests and the values 
were shown in table 6.15. All the tablets complied with the pharmacopoeial standards. 
All the formulations showed good floating lag time and remained buoyant for more 
than 12 hours except formulation F13 which remained buoyant for 11 hours. The in 
vitro release data for formulations (F10-F13) was presented in table 6.16 and fig 6.10. 
The release rate followed zero-order release kinetics (fig 6.11) and the data was fitted 
in the Peppas plots (fig 6.12).The exponential coefficient from the Peppas plots was 
found to be in between 0.63 to 0.94, indicating non fickian mechanism of drug 
release. Drug release kinetic data was presented in table 6.17. The release rate of 
Levofloxacin hemihydrate was found to be affected by the concentration of the 
polymer used in the preparation of tablets.Based on the release rate, the order of drug 
release from the formulations was in order of F12>F11>F10 after 12 hours. 
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The results of swelling index studies for tablets formulated with gum 
kondagoguare shown in table 6.18 and figure 6.13. The formulation containing 
HPMC K 100 M and gum kondagoguin a ratio of 1:1 showed higher swelling index. 
 
Table 7.1: Comparativeinvitro release parameters of Levofloxacin hemihydrates 
floating tablets formulated with various natural polymers and HPMC K 100 
M.(1:1 ratio) 
Formulation % Drug release at Release Rate Constant 
 
end of 12 hours. 
k0 
 
(mg/hr)   
   
F3(Levofloxacin+ gum karaya) 94.26 22.77 
   
F 7 (Levofloxacin+xanthumgum) 73.33 15.11 
   
F 11(Levofloxacin+ gum kondagogu) 85.69 19.43  
 
 
From the above table (7.1) it is clearly evident that the invitro release of drug 
from the floating tablet was influenced by nature of natural polymer. Based on the 
release rate constant and % of drug release at the end of 12 hours the release retarding 
capacities of the natural polymers were arranged in the following order. Xanthum 
gum> gum kondagogu>gum karaya. 
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7.7. IR Spectral studies. 
 
The IR Spectrum of Levofloxacin hemihydrates and Levofloxacin 
 
hemihydrates were shown in figures 6.18-6.22. 
 
  Characteristicstretching 
S.No. Formulation 
   
Carbonyl Aromatic Carbonyl 
  C=O C-H O-H 
     
1 Levofloxacin hemihydrate 1724.8cm
- 
2935.62cm
- 
3247.31cm
- 
     
2 Levofloxacin + gum karaya 1718.10cm
- 
2928.95cm
- 
3248.67cm
- 
     
3 Levofloxacin +xanthum gum 1719.24cm
- 
2931.73cm
- 
3241.94cm
- 
     
4 Levofloxacin +gumkondagogu 1717.61cm
- 
2929.75cm
- 
3254.88cm
- 
     
 
 
 
The obtained IR spectra of Levofloxacin hemihydrate and combination of 
Levofloxacin hemihydrate with natural polymers were identical. The IR spectra of the 
pure drug and drug in combination with natural polymers indicated that, no chemical 
interaction occurred between the drug, Levofloxacin hemihydrate and the excepients 
used. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
92 
8. SUMMARY AND CONCLUSION 
 
 Floating tablets of Levofloxacin hemihydrate prepared usinggumkaraya, 
xanthumgumandgumkondagogu showed controlled release for a prolonged 
period of time.


 The natural polymers used showed drug release retarding nature and the 
release retarding nature was in order of Xanthum gum> gum kondagogu> gum 
karaya.


 Compared to other gums used Xanthumgumhashigh viscosity value and good 
drug release retarding capacity.


 There is a similarity between the viscosities of the polymers and their release 
retarding profiles.

 

 The floating tablets prepared only with HPMC K 100 M had shown much 
lesser drug release than the combination of natural polymer (gum kondagogu/ 
gum karaya) and HPMC K 100 M.Whereas in case of formulations prepared 
with xanthum gum and HPMC K 100 M shows much lesser drug release than 
the formulations prepared with HPMC K 100 M alone. 
 
 The concentration of NaHCO 3 influences the lag time. In this investigation 
20-23% NaHCO 3 was selected as optimized concentration.


 The FT-IR studies clearely indicates that there are no drug and polymer 
interactions.


 PreparedLevofloxacin hemihydrate floating tablets complies with the 
specifications of the Pharmacopoeial standards.

 
 
From this study it could be concluded that natural polymers can be used in the 
preparation of floating tablets and in combination with synthetic polymers. Floating 
tablets of Levofloxacin hemihydrate prepared by employing natural polymers could 
be used for treatment of gastric ulcers caused by H.pylorii infection by prolonging the 
gastric residence time and its controlled release in the gastric environment thus 
completely eradicating the Helicobacter pylorifrom GIT. 
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Recommendations 
 
The following recommendations are suggested for future extension of this 
experimental work. 
 
 Selection of suitable packaging materials.

 Stability studies on the finished dosage form.

 In vivo studies on suitable animal and assessment of various pharmacokinetic 
and pharmacodynamic evaluation of drug.

 Physico-chemical characterization of extracted natural polymers.
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